Marshall University

Marshall Digital Scholar
Theses, Dissertations and Capstones
2022

Investigation of the Effects of Prenatal Drug Exposure on
Astrocyte-Mediated Synaptogenic Signaling
Taylor Christian Boggess

Follow this and additional works at: https://mds.marshall.edu/etd
Part of the Medicine and Health Sciences Commons, Neuroscience and Neurobiology Commons, and
the Toxicology Commons

INVESTIGATION OF THE EFFECTS OF PRENATAL DRUG EXPOSURE ON
ASTROCYTE-MEDIATED SYNAPTOGENIC SIGNALING

A dissertation submitted to
the Graduate College of
Marshall University
in partial fulfillment of
the requirements for the degree of
Doctor of Philosophy
in Biomedical Research
by
Taylor Christian Boggess
Approved by
Dr. W. Christopher Risher, Committee Chairperson
Dr. Richard Egleton
Dr. Philippe Georgel
Dr. Brandon Henderson
Dr. Mary Payne

Marshall University
May 2022

ii

© 2022
Taylor Christian Boggess
ALL RIGHTS RESERVED

iii

ACKNOWLEDGMENTS
This dissertation, and the years of work that comprise it, would not have been possible
without the help and support of several people. I would first like to thank my parents whose
unwavering encouragement and love pushed me to always give my best effort and carried me
through periods of self-doubt or discouragement. I am also grateful to my extended family,
particularly my grandmother, aunts, and cousins, who helped in my life outside of the lab. Next,
I would like to thank my mentor Dr. Chris Risher for his patience and willingness to guide me
through the majority of the laboratory techniques required for the completion of this dissertation.
He also assisted me greatly in the navigation of complex processes common in the research field,
such as writing scientific articles, applying for grants, and preparing presentations. Dr. Risher
always served as a positive example of what the life of a research scientist could be. The other
members of the Risher lab, as well as members of Dr. Louise Risher’s lab, also provided a great
deal of assistance and instruction during my research pursuits. Finally, I would like to thank the
other members of my graduate committee, Dr. Henderson, Dr. Egleton, Dr. Georgel, and Dr.
Payne, for making their resources and knowledge available to me. Whether it was in the
classroom, in the clinic, or in the lab, I knew I always I had experienced, knowledgeable
professionals from whom I could seek guidance and on whom I could rely for aid.
All of the people I have acknowledged here have shaped my life in ways that are hard to
quantify. I hope to continue to shape my life in such a way that my talents and experience are
best utilized to improve the lives of others and have a positive impact on the world. The pursuit
of this goal will not be feasible without the aid and support of other people, and so I have taken
this opportunity to sincerely thank the people who have aided and supported me up to this point.
My future is all the brighter because of you.

iv

TABLE OF CONTENTS
List of Tables .................................................................................................................................. x
List of Figures ................................................................................................................................ xi
Abstract ........................................................................................................................................ xiv
Chapter 1 ......................................................................................................................................... 1
Neonatal Abstinence Syndrome .......................................................................................... 1
The Endogenous Opioid System Serves a Key Role in CNS Development....................... 4
Exogenous Opioids Have Multiple Effects Within the CNS .............................................. 5
Drugs of Abuse Can Interfere with the Normal Development of Neurons in the CNS.... 10
Drugs of Abuse Can Interfere with the Normal Function and Development of Glia in the
CNS ................................................................................................................................... 11
Effects of Prenatal Gabapentin Exposure ......................................................................... 14
Changes in Size and Structure in the CNS Associated with Prenatal Drug Exposure ..... 16
Prenatal Drug Exposure is Associated with Changes in Behavior ................................... 17
Goals of this Dissertation .................................................................................................. 21
Chapter 2 ....................................................................................................................................... 23
Introduction ....................................................................................................................... 23
Materials and Methods ...................................................................................................... 23
Results ............................................................................................................................... 24
Few Patients Returned for More than One Follow-Up Appointment ................... 24

v

Certain Drugs Were Commonly Misused by Patient Mothers ............................. 25
Many Patients Did Not Reach Developmental Milestones on Time .................... 26
Certain Medical Issues Were Frequently Observed Among the Patients ............. 28
Certain Medical Issues Were Common Among the Mothers of Patients ............. 28
Medicaid was Primary Medical Insurance for Majority of Patients ..................... 29
A Plan for Care was Developed to Meet the Needs of Each Patient .................... 30
Discussion ......................................................................................................................... 31
Chapter 3 ....................................................................................................................................... 36
Introduction ....................................................................................................................... 36
Materials and methods ...................................................................................................... 37
Results ............................................................................................................................... 46
Drug Accumulation was Confirmed in Neonatal Mouse Brain Tissue ................ 46
Body Mass of Dams and Pups Impacted by Drug Treatment, Sex, and Expression
of α2δ-1 ................................................................................................................. 47
Early Life Exposure to Buprenorphine Increases Excitatory Synapses in the
Mesolimbic Dopamine Pathway ........................................................................... 48
Combined Buprenorphine/Gabapentin Exposure Decreases Inhibitory Synapse
Number ................................................................................................................. 51
α2δ-1 Haploinsufficiency Results in Region- and Treatment-Specific Differences
in Synaptic Connectivity ....................................................................................... 53
Discussion ......................................................................................................................... 53
vi

Drug Dosing Paradigm Correlates ........................................................................ 57
Gabapentin, α2δ-1, and Astrocytes ....................................................................... 58
Chapter 4 ....................................................................................................................................... 60
Introduction ....................................................................................................................... 60
Materials and methods ...................................................................................................... 64
Results ............................................................................................................................... 72
Body Mass of Pups Impacted by Drug Treatment and Expression of α2δ-1........ 72
P21 Immunohistochemistry .................................................................................. 73
Early Life Exposure to Gabapentin Decreased Excitatory Synapses in the
Mesolimbic Dopamine Pathway ........................................................................... 73
Decreased Expression of α2δ-1 Significantly Decreased the Number of Excitatory
Synapses ................................................................................................................ 76
Inhibitory GABAergic Synapses Were Significantly Impacted by Early Life
Exposure to Buprenorphine, as a Single Treatment and in Combination with
Gabapentin ............................................................................................................ 80
Decreased Expression of α2δ-1 Significantly Decreased the Number of Inhibitory
Synapses, But Not in Mice Treated with Gabapentin ........................................... 81
P70 Immunohistochemistry .................................................................................. 85
Changes in Excitatory Synapses Resulting from Early Life Drug Exposure
Persisted into Adulthood ....................................................................................... 85

vii

Persistent Effects of Early Life Drug Exposure on Excitatory Synapses Influenced
by Expression of α2δ-1 ......................................................................................... 86
Inhibitory Synapses Were Significantly Impacted by Early Life Exposure to Both
Buprenorphine and Gabapentin ............................................................................ 89
Influence of α2δ-1 Expression on Inhibitory Synapses not Observed in Mice with
Early Life Drug Exposure ..................................................................................... 89
Excitatory Synapses Generally Decrease with Age .............................................. 92
Inhibitory Synapses Generally Decrease with Age, But Not in Gabapentin Treated
Mice ...................................................................................................................... 96
Behavioral Studies .............................................................................................. 100
Early Life Drug Exposure Did Not Have Any Significant Effect on Performance
During Light/Dark Testing ................................................................................. 100
Possible Changes in Locomotor Function and Freezing Behavior in Open Field
............................................................................................................................. 102
Enhancement of Conditioned Place Preference Not Observed in Drug Treated
Mice .................................................................................................................... 104
Decline After Day 1 Performance in FR1 Schedule Self-Administration .......... 107
FR3 Schedule Self-Administration Not Enhanced In Mice that Demonstrated
Possible Reinforcement ...................................................................................... 107
Discussion ....................................................................................................................... 110

viii

Early Life Drug Exposure Significantly Impacts Astrocyte-Mediated
Synaptogenesis via α2δ-1 ................................................................................... 110
Effects of Early Life Drug Exposure on Synaptogenesis Are Not Fully
Ameliorated with Age ......................................................................................... 112
Early Life Drug Exposure Resulted in Few Significant Changes in Anxiety-Type
or Locomotor Behaviors ..................................................................................... 113
Reward Seeking Behaviors were not Significantly Affected by Early Life Drug
Exposure or Expression of α2δ-1 ........................................................................ 115
Chapter 5 ..................................................................................................................................... 119
Reflection on Major Findings from These Investigations .............................................. 119
Potential Weaknesses and Directions for Future Studies ............................................... 120
Final Remarks ................................................................................................................. 125
References ................................................................................................................................... 126
Appendix A: Approval Letter ..................................................................................................... 161

ix

LIST OF TABLES
Table 1

Drugs Misused by the Mothers of Patients During Their Pregnancies....................26

Table 2

Number of Patients Who Reached Each CDC Developmental Milestone .............27

Table 3

Common Medical Issues Observed Among Lily’s Place Patients at Follow-Up
Appointments.........................................................................................................29

Table 4

Common Medical Diagnoses Among the Mothers of Lily’s Place Patients............29

Table 5

Plans for Care Developed for Patients at the End of Follow-Up Appointments......31

Table 6

Drug Concentrations (Shown as Mean ± SEM) Within Brain Tissue Lysates from
Drug-Exposed Newborn C57Bl/6/J Pups Determined via Liquid ChromatographyTandem Mass Spectrometry...................................................................................46

Table 7

Body Mass of Dams and Pups (Shown as Mean ± SEM) in Each Treatment and
Genotype Group at P21 Perfusion Date..................................................................48

Table 8

Body Mass of α2δ-1Thy1 Dams and P21 Pups in Each Treatment and Genotype
Group at Perfusion Date.........................................................................................74

Table 9

Body Mass of P70 α2δ-1Thy1 Mice in Each Treatment and Genotype Group at
Perfusion Date........................................................................................................75

x

LIST OF FIGURES
Figure 1

Brain Regions of Interest Within Mesolimbic Dopamine Pathway..........................8

Figure 2

The Tripartite Synapse and the Interactions Between Thrombospondins (TSP),
α2δ-1, and Gabapentin (GBP)................................................................................14

Figure 3

Patient Appearance for Follow-Up Appointments.................................................25

Figure 4

Visual Representation of Immunohistochemistry Staining....................................45

Figure 5

Increased Excitatory Synapses with Early Life Buprenorphine Exposure..............50

Figure 6

Dual Exposure to Buprenorphine and Gabapentin Decreased Inhibitory Synapses
at P21......................................................................................................................52

Figure 7

Altered Excitatory Synaptic Connectivity Following Early Life Drug Treatment in
α2δ-1 Haploinsufficient Mice................................................................................54

Figure 8

α2δ-1-Influenced Changes in Inhibitory Synapse Development in Drug-Exposed
Pups........................................................................................................................55

Figure 9

Confirmation of Forebrain-Specific Conditional α2δ-1 Knockout Mouse.............62

Figure 10

Schedule for Behavioral Studies for Each Mouse in the P70 Group, Beginning at
P22 and Ending at P70............................................................................................70

Figure 11

Formation of Excitatory Synapses Decreased with Early Life Gabapentin
Exposure................................................................................................................77

Figure 12

Presence of α2δ-1 Significantly Impacted Excitatory Synapse Number Within the
Anterior Cingulate Cortex......................................................................................78

Figure 13

Response to the Combination of Buprenorphine and Gabapentin Determined by
Presence of α2δ-1 Within the Nucleus Accumbens................................................79

xi

Figure 14

Response to Buprenorphine Impacted by the Presence of α2δ-1 in Prefrontal
Cortex.....................................................................................................................80

Figure 15

Development of Inhibitory Synapses Impacted by Buprenorphine........................82

Figure 16

Presence of α2δ-1 Significantly Impacted Inhibitory Synapse Number Within the
Anterior Cingulate Cortex......................................................................................83

Figure 17

Buprenorphine Can Affect Changes in Inhibitory Synapse Number Within the
Nucleus Accumbens...............................................................................................84

Figure 18

Gabapentin Capable of Interfering with α2δ-1 Related Decrease in Inhibitory
Synapse Number Within the Prefrontal Cortex......................................................85

Figure 19

Drug Induced Changes in Excitatory Synapse Number Persist into Adulthood......87

Figure 20

Persistent Effects of Early Life Buprenorphine Exposure Influenced by
Haploinsufficiency of α2δ-1...................................................................................88

Figure 21

Early Life Drug Exposure Produces Persistent Changes in Inhibitory Synapse
Number..................................................................................................................90

Figure 22

Effects of Early Life Drug Exposure on Inhibitory Synapse Number is Less
Impacted by Haploinsufficiency of α2δ-1 Over Time............................................91

Figure 23

Increase in Age Generally Associated with Decrease in Excitatory Synapse Number
Within the Anterior Cingulate Cortex.....................................................................93

Figure 24

Age Related Decrease in Excitatory Synapse Number Not Equal Across Drug
Treatment Groups Within the Nucleus Accumbens................................................94

Figure 25

Changes in Excitatory Synapse Number in Gabapentin Treatment in
Haploinsufficent Mice Not Altered by Age Within the Prefrontal Cortex..............95

xii

Figure 26

Expression Level of α2δ-1 Influences Age-Related Changes in Inhibitory Synapses
Within Anterior Cingulate Cortex..........................................................................97

Figure 27

Inhibitory Synapses Increase with Age in Gabapentin Treated Mice Within the
Nucleus Accumbens...............................................................................................98

Figure 28

Inhibitory synapses increase with age in gabapentin treated mice Within the
Prefrontal Cortex....................................................................................................99

Figure 29

Light/Dark Testing Performance Not Impacted by Early Life Drug Exposure or
Expression Level of α2δ-1....................................................................................101

Figure 30

Anxiety and Locomotor Activity in Open Field Testing Potentially Impacted by
Early Life Drug Exposure.....................................................................................103

Figure 31

Performance in Open Field Not Impacted by Expression Level of α2δ-1.............105

Figure 32

Neither Drug Treatment Nor α2δ-1 Expression Significantly Affected Conditioned
Place Preference...................................................................................................106

Figure 33

Number of Nose Pokes Declined After First Day of 10-Day FR1 SelfAdministration.....................................................................................................108

Figure 34

No Significant Differences Observed Among the Mean Number of Nose Pokes of
from Last 2 Days of FR3 Self-Administration in Mice That Demonstrated
Reinforcement......................................................................................................109

xiii

ABSTRACT
One of the most significant outcomes of the rise in rates of opioid abuse in the United States has
been a dramatic increase in the incidence of neonatal abstinence syndrome (NAS), the clinical
diagnosis for the collection of withdrawal-like signs and symptoms commonly observed in the
newborns of mothers who abused certain drugs, such as opioids, during pregnancy. While a great
deal of research has investigated the short-term symptoms and potential treatments for NAS,
including my own studies to identify emerging trends among a local population of NAS patients,
there remains a critical need to investigate the long-term effects of prenatal drug exposure on
neurological development. A potential route through which drugs of abuse likely interact with
the developing nervous system lies in astrocyte-mediated synaptic development, more
specifically in signaling involving thrombospondins, a class of astrocyte secreted glycoproteins
that act through binding to the neuronal cell surface receptor α2δ-1. α2δ-1 is also the receptor for
the antiepileptic drug gabapentin. Co-abuse of opioids and gabapentin during pregnancy is
associated with a unique presentation of NAS. I have therefore hypothesized that prenatal
exposure to drugs of abuse leads to significant disruptions in astrocyte mediated synaptogenic
signaling, resulting in permanent deficits in synapse formation and alterations in behaviors
associated with addiction. To test this, I treated pregnant mice transgenic for α2δ-1 with one of
four treatments: the opioid drug buprenorphine, gabapentin, a combination of both drugs, or a
vehicle control. α2δ-1 wild-type, heterozygous, and knockout littermate pups of both sexes at 21
days of age were used for studies involving immunohistochemistry and confocal fluorescence
microscopy to investigate synaptic connectivity within brain regions associated with reward. A
second cohort of pups at 70 days of age underwent the same studies after first undergoing
behavioral experiments examining anxiety, locomotion, and reward seeking. By completing
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these studies, I hoped to contribute to a greater understanding of the effects of prenatal opioid
exposure on neurological and behavioral development that would inform parents, healthcare
providers, and educators looking to meet the unique developmental and educational needs of
children impacted by drug abuse.
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CHAPTER 1
INTRODUCTION
The use of derivatives of the opium poppy (Papaver somniferum) to treat pain and induce
euphoria likely predates the oldest surviving records of human history (Bandyopadhyay, 2019;
Brownstein, 1993; Dhawan et al., 1996; Pasternak & Pan, 2013). It is also likely that these
derivatives and the synthetic drugs modeled after them have led to misuse and addiction for
nearly as long. It is only within the past few decades, however (AHRQ, 2021; Scholl L, 2019;
USDHHS, 2015), that rates of opioid abuse have risen to levels high enough to have a significant
impact on the wider society and be labeled an epidemic, due predominantly to factors such as
evolving philosophies surrounding the treatment of pain, the development of increasingly
effective and potent drugs, and changes in the prescribing practices of physicians (Cerdá et al.,
2015; DeWeerdt, 2019; Haight et al., 2018; Kolodny et al., 2015; Tsang et al., 2008; USDHHS,
2015). The full consequences of this widespread rise in substance abuse are still in the process of
being understood with researchers from a wide variety of backgrounds and specialties
approaching different aspects of the problem.
Neonatal Abstinence Syndrome
One direct result of the rise in rates of opioid use disorder (OUD) that is being heavily
researched is the dramatic rise in the rates of neonatal abstinence syndrome (NAS) (Desai et al.,
2014; Haight et al., 2018; Tolia et al., 2015; Winkelman et al., 2018). NAS is the clinical
diagnosis used to describe the withdrawal-related signs and symptoms commonly observed in the
newborns of mothers who abused certain drugs, such as opioids, during pregnancy (the condition
can also be referred to as neonatal opioid withdrawal syndrome, or NOWS, in cases where
opioids are known to be the primary substance abused during the pregnancy). Signs and
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symptoms of NAS typically begin within 72 hours after birth and commonly include irritability,
tremors, excessive crying, sneezing, excessive yawning, tachycardia, hypertension, poor feeding,
diarrhea, and, in some severe cases, seizures (Kocherlakota, 2014; Raffaeli et al., 2017). Use of
drugs of abuse, such as opioids, during pregnancy has also been correlated with increased risk of
sudden infant death syndrome (SIDS; risk ratio as high as 3.6 for methadone-exposed infants)
(Cohen et al., 2015; Kandall et al., 1993) and death within the first two years of life (Ostrea et
al., 1997). Numerical scoring scales, such as the Finnegan Neonatal Abstinence Scoring System
(Finnegan et al., 1975) are used to evaluate the severity of symptoms and help direct decisions
concerning treatment and care (Kocherlakota, 2014). Length of stays in hospital neonatal
intensive care units or similar dedicated treatment facilities average 16 days for affected infants
(Hudak & Tan, 2012) but can widely vary. Pregnant women with OUD are commonly
encouraged to enroll in medication-assisted treatment (MAT), which combines the prescription
of less-addictive opioid drugs, typically methadone or buprenorphine, with behavioral counseling
and other forms of prenatal support in order to treat their addiction and hopefully improve health
outcomes for both the mother and her child. However, emerging evidence asserts that any opioid
use during pregnancy, even when administered as part of a medical treatment, can have
deleterious effects on the developing fetus and MAT does not eliminate the potential for NAS
(Belcheva et al., 1998; Burke & Beckwith, 2017; Grecco et al., 2021; H. Johnson et al., 1984;
Kayemba-Kay’s & Laclyde, 2003).
NAS represents a significant health concern for affected infants and an emotional toll on
the families of those infants. It also represents a significant financial burden (Patrick et al., 2015;
S. Patrick et al., 2012). Total hospital costs to treat NAS patients who were covered by Medicaid
increased from $65.4 million in 2004 to $462 million in 2014 (Winkelman et al., 2018). These

2

rising medical costs are further complicated by the fact that, while socio-economic status is not
necessarily correlated with substance use, a large proportion of substance use disorder patients
come from lower socio-economic backgrounds, a group that also historically has poorer access to
quality healthcare in general (Becker & Newsom, 2003; Braveman & Gottlieb, 2014; Hanson &
Chen, 2007; M. Kim et al., 2018; M. Patrick et al., 2012).
While OUD and NAS are global issues, the United States has been, and remains, the most
severely impacted country (Lancet, 2022). The national rate of NAS in the United States was 6.8
per 1000 neonatal hospitalizations in 2018 compared to 1.5 in 1999 (AHRQ, 2021; Haight et al.,
2018). However, rates can vary widely between different states and within the same state.
Appalachia and more rural regions in the country have been disproportionately affected by OUD
and NAS (J. Brown et al., 2018; Hayes & Brown, 2012; Patrick et al., 2015). In West Virginia
for example, where access to treatment facilities for opioid abuse is limited compared to other
states (J. Brown et al., 2018), the rate of NAS from October 2016 to December 2017 was 52.6
cases per 1,000 live births (Umer et al., 2019). In 2018, the statewide rate was slightly lower at
49.6 per 1000 live births (7.3× the national average) but was still the highest rate of any state in
the country (AHRQ, 2021).
The serious emotional toll for the families of affected children and the significant burdens
placed on healthcare providers associated with these high incidence rates of NAS have prompted
considerable research efforts into better understanding the mechanisms of NAS and improving
clinical care and treatment for NAS affected infants. However, compared to the number of
research studies that have investigated mechanisms and treatments, information regarding the
long-term effects of prenatal exposure to drugs of abuse on neurological development, in humans
or in animal models, is limited. Additional research into this area is necessary in order for
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healthcare providers, educators, and parents better meet the specific needs of affected children as
they grow and develop.
The Endogenous Opioid System Serves a Key Role in CNS Development
All opioid drugs interact with the human body via binding to one or members of a class
of G-protein coupled receptors simply referred to as opioid receptors (McDonald & Lambert,
2005). These receptors are expressed in varying levels throughout the body, including the CNS
(Merrer et al., 2009; Peng et al., 2012; Rius et al., 1991; Zhu et al., 1998). Each receptor type
binds preferentially with one or more members of a group of peptide hormones known as
endogenous opioids (McDonald & Lambert, 2005; Zagon & McLaughlin, 2017). The
endogenous opioid β-endorphin appears to bind strongly to all three of the classically known
receptors: the µ opioid receptor (MOR), the δ opioid receptor (DOR), and the κ opioid receptor
(KOR) (McDonald & Lambert, 2005). The endogenous opioids endomorphin 1 and 2 bind most
strongly to the MOR, leu- and met-enkephalin bind most strongly to the DOR, and dynorphins A
and B bind most strongly to the KOR (Dhawan et al., 1996; McDonald & Lambert, 2005; Zagon
& McLaughlin, 2017). The more recently characterized endogenous opioid nociceptin/orphanin
FQ opioid peptide (N/OFQ) binds to the most recently discovered receptor, the N/OFQ opioid
receptor (NOR) (Toll et al., 2016). The interactions between endogenous opioids and their
receptors are often collectively referred to as the endogenous opioid system (McDonald &
Lambert, 2005). This system is involved in the activity and regulation of many different
biological processes, including analgesia, respiratory/cardiac function, intestinal transit, mood,
and hormone secretion, and is essential for normal development and function (Dhawan et al.,
1996; Rius et al., 1991; Tan et al., 2018).
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There is reason to believe that endogenous opioids and their receptors are particularly
vital to healthy nervous system development. For example, MOR and KORs have been detected
on the surfaces of rodent embryonic stem cells and neural progenitor cells with evidence that the
binding of endogenous opioids can induce embryonic stem cells to differentiate via the
extracellular signal-regulated kinase (ERK)/ mitogen-activated protein (MAP) kinase signaling
pathway (E. Kim et al., 2006; Tan et al., 2018). The localization of opioid receptors to different
regions of the brain may also have a significant impact on development. Immature mice have
been shown to have a higher percentage of MOR expression within known sites of neurogenesis,
namely the subventricular zone and striatum, compared to adult mice (Stiene-Martin & Hauser,
1991). In neonatal rats, expression of KORs within known sites of cellular proliferation and
neurogenesis, including the ventricular and subventricular zones and the hippocampus, has been
shown to be higher compared to adults (Tan et al., 2018). Given the importance of endogenous
opioids and their receptors in the developing CNS, an introduction of exogenous opioids could
have a lasting, dramatic impact on this process.
Exogenous Opioids Have Multiple Effects Within the CNS
All opioid drugs, whether derived from natural sources or developed synthetically,
interact with the human body primarily through the same class of receptors as endogenous
opioids. Morphine, the prototypical opioid, and its derivatives (heroin, fentanyl, oxycodone, etc.)
are primarily active at MORs but also act as weaker KOR and DOR agonists (McDonald &
Lambert, 2005). These drugs are believed to alleviate pain through two separate mechanisms: 1.
By binding to opioid receptors on the axon terminals of nociceptive afferent neurons from the
peripheral nervous system within the dorsal horn of the spinal cord to depress the release of
neurotransmitters, predominantly substance P and glutamate; and 2. By binding to opioid
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receptors within the CNS (particularly the midbrain, brainstem, and thalamus) to activate
descending inhibitory pain pathways (Doyle & Murphy, 2018; Inturrisi, 2002; Lipp, 1991;
Lueptow et al., 2018; Pasternak & Pan, 2013). Methadone is another derivative of morphine that
also has a high affinity for the MOR and can also be prescribed for pain relief. However,
methadone also has additional properties, such as a delayed onset of action and longer half-life
(Ball & Ross, 2012; R. Brown et al., 2004; Chestnut, 2020), that have led to its use as a
maintenance treatment for OUD ("Dose-response effects of methadone in the treatment of opioid
dependence," 1993; Ling et al., 1976). In contrast, the more recently developed opioid
buprenorphine, which is also used as an analgesic and has been increasingly used in the
treatment of OUD, is a derivative of the opiate alkaloid thebaine. It has been shown to be a
partial agonist at MORs but an antagonist at KORs and DORs (Martin et al., 2001; Welsh &
Valadez-Meltzer, 2005), likely contributing to its effectiveness as a maintenance therapy.
Intriguingly, however, buprenorphine’s metabolite norbuprenorphine is an agonist at the DOR
and a partial agonist at MORs and KORs (Huang et al., 2001). Clearly, despite all being
classified as opioids, individual drugs within this classification can vary widely in both their
receptor binding profiles and their pharmacokinetics, thus determining their applications in
medicine and potentials for harm or abuse.
It is widely accepted that the primary mechanism by which opioids induce reward and
hold the potential for abuse and addiction is via interactions within the mesolimbic dopamine
pathway (Carlezon & Wise, 1996; Di Chiara et al., 2004; S. Johnson & North, 1992; Pierce &
Kumaresan, 2006; Wachtel et al., 1989) (Figure 1A). The mesolimbic dopamine pathway,
sometimes referred to as the dopamine reward pathway, normally functions to encode
experiences as novel (Bunzeck & Düzel, 2006; Bunzeck et al., 2007; Kutlu et al., 2021) and
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pleasurable in order to reinforce future behaviors in an attempt to seek out similar experiences
(Knutson & Cooper, 2005; Lisman & Grace, 2005; Wittmann et al., 2005). This process begins
within the midbrain in the ventral tegmental area (VTA), where the cell bodies of dopaminergic
neurons extend axonal processes to other regions of the brain. The most prominent of these brain
regions are the nucleus accumbens (NAC) within the striatum and the prefrontal cortex (PFC)
(Adinoff, 2004; Carr et al., 1999; Han et al., 2017; Lisman & Grace, 2005). Increased phasic
release of dopamine within the NAC in response to external stimuli has been shown to reinforce
pleasurable behaviors including eating food, engaging in sexual activity, or consuming alcohol
and/or drugs of abuse (Lingford-Hughes & Kalk, 2012). Opioids act within the VTA by binding
to opioid receptors on the surface of GABAergic interneurons that exert inhibitory control on
neighboring dopaminergic neurons (Bouarab et al., 2019; Jalabert et al., 2011; S. Johnson &
North, 1992), effectively inhibiting the release of GABA and disinhibiting the release of
dopamine.
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Figure 1: Brain Regions of Interest Within Mesolimbic Dopamine Pathway
(A) Diagram of mouse brain highlighting regions associated with mesolimbic dopamine pathway
and the known connections between them (PFC, prefrontal cortex; ACC, anterior cingulate
cortex; NAC, nucleus accumbens; VTA, ventral tegmental area; Hippo, hippocampus; Amyg,
amygdala). (B–D) Representative fluorescent confocal microscopic images of excitatory synaptic
immunohistochemistry staining (presynaptic VGluT1, green; postsynaptic PSD95, red) at 10X
and 63X magnification of the (B) ACC, (C) NAC, and (D) PFC.

Interactions between brain regions, both within and outside the mesolimbic dopamine
pathway, modulate the activity of this pathway and influence reward motivated behavior. The
PFC, the brain region most associated with decision making and impulse control (Holt et al.,
2008; Knutson & Cooper, 2005; Pryor & Veselis, 2006), projects to the NAC and modulates its
activation in response to dopamine release (Carr et al., 1999; Han et al., 2017; McFarland et al.,
2003; Pierce & Kumaresan, 2006; Rebec & Sun, 2005). It has been shown that projections from
the medial PFC to the NAC are involved in reinstatement of drug-seeking behavior in response

8

to stress or drug-associated cues (McFarland et al., 2003; Rebec & Sun, 2005). It has also been
shown that the PFC is largely responsible for reward prediction during the performance of
behavioral tasks (Knutson & Cooper, 2005). The hippocampus, a brain region crucial to learning
and memory (Anand & Dhikav, 2012; Rubin et al., 2014), appears to form a functional loop with
the VTA to promote the seeking out of novel experiences and expecting reward when engaging
in behaviors associated with pleasurable memories (Lisman & Grace, 2005; Wittmann et al.,
2005). The anterior cingulate cortex (ACC) is involved in a variety of functions, including
reward anticipation, motivational persistence, and modulation of goal oriented motor activity
(Blanchard et al., 2015; Walton et al., 2003), and has been shown to influence motivation via
modulation of VTA activity (Elston & Bilkey, 2017; Narita et al., 2010; Y. Yuan et al., 2009).
The amygdala is largely known to be a center for the processing of emotions, particularly fear
(Balleine & Killcross, 2006; Bonnet et al., 2015). However, the amygdala is also known to
interact with the hippocampus to attribute emotional coding to memories and has been shown to
interact with the NAC and VTA to modulate stress and addiction (Belujon & Grace, 2011; Chi
Yiu & Mogenson, 1982; Hurd et al., 1999; C. Nguyen et al., 2021). The interconnectedness of
these brain regions may indicate the potential for opioid induced changes in structure or function
within one region to impact other regions as well. Understanding what effects drugs of abuse,
such as opioids, can have on the normal development, structure, and function of the mesolimbic
dopamine pathway and the CNS in general will be crucial to better understanding and treating
substance abuse.
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Drugs of Abuse Can Interfere with the Normal Development of Neurons in the CNS
Given the importance of the endogenous opioid system in development and the impact
exogenous opioids can have on CNS function, the question of how opioids could potentially
affect the development of the CNS naturally arises. In animal models, prenatal opioids have been
shown to stunt the proliferation and development of neurons within the CNS. Levels of neuronal
specific protein markers (Neu-N and MAP-2) as well as stem/progenitor biochemical markers of
the neural lineage (nestin, Sox2, KLF4, and doublecortin) were reduced in 21-day-old rats that
had been exposed to buprenorphine during prenatal development (Wu et al., 2014). This same
group of 21-day-old rats also showed decreased brain-derived neurotrophic factor (BDNF)
expression and signaling (Wu et al., 2014). BDNF is critical is critical in CNS development. In
particular, signaling between BDNF and the receptor TrkB is vital for neurogenesis, axon
growth, and synaptic plasticity (Cohen-Cory et al., 2010; Kramár et al., 2012). The relationship
between BDNF and exogenous opioids is likely significant given that plasma levels of BDNF
were found to be increased in 2-day-old human infants diagnosed with NAS compared to healthy
infants (Subedi et al., 2017). Epigenetic modifications resulting from opioid exposure may
explain this relationship, given that expression of BDNF is highly epigenetically regulated
(Browne et al., 2020; K.-W. Chen & Chen, 2017).
Altered expression of growth factors and signaling molecules do not appear to be the only
mechanism through which opioids affect neuronal development. In free-floating cultured rat
cortical neurospheres, buprenorphine was shown to reduce proliferation of neural
stem/progenitor cells (Wu et al., 2014). It has also been shown, within rats, that opioids alter
neuronal expression of apoptotic proteins (namely caspase-3, Bcl-2, and Bax) particularly within
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the hippocampus (Wang & Han, 2009). Dysregulation of apoptosis could lead to inappropriate
cell death and potentially interfere with normal neuronal development.
In addition to affecting proliferation and overall numbers of neurons in the developing
CNS, prenatal opioids also appear to influence neuronal growth and maturation. Neurons isolated
from the somatosensory cortices of heroin-exposed 3-day-old mouse pups possessed fewer and
shorter dendrites compared to neurons from control pups (Lu et al., 2012). This change in
dendritic development could impede synaptic connectivity and inter-neuronal communication
throughout the brains of these pups.
Drugs of Abuse Can Interfere with the Normal Function and Development of Glia in the
CNS
While studies examining the effects of prenatal drug exposure in the CNS have
predominantly focused on the development of neurons, the development of nonneuronal glial
cells has also been shown to be influenced by both the endogenous opioid system (Stiene-Martin
& Hauser, 1991) and by exogenous drugs of abuse (Narita et al., 2006). There are a variety of
different glial cell types, each with distinct and vital roles in the development, function,
maintenance, and repair of the CNS. Oligodendrocytes (Kettenmann & Verkhratsky, 2011;
Sanchez et al., 2008; Tan et al., 2018; Vestal-Laborde et al., 2014) and microglia (Maduna et al.,
2019; Schwarz & Bilbo, 2013; Zamani et al., 2022) have been implicated in prenatal opioidinduced changes in neurological development. However, an increasing amount of evidence
points to astrocytes as being the glial cell type most involved in the changes within the CNS in
response to prenatal drug exposure.
Astrocytes are the most numerous type of glia in the CNS and are involved in a number
of vital processes (Sidoryk-Wegrzynowicz et al., 2011; Volman et al., 2012) including, but not
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limited to, maintenance of the blood brain barrier (Allen & Lyons, 2018), regulation of
extracellular ion balance (Volman et al., 2012), regulation of the concentrations of
neurotransmitters in the extracellular space (Boddum et al., 2016; Minelli et al., 1996; A. Q.
Nguyen et al., 2020), glutamate uptake and release (Parpura & Haydon, 2000), and regulation of
synaptic development within the CNS (Allen & Lyons, 2018; Bosworth & Allen, 2017;
Christopherson et al., 2005; Clarke & Barres, 2013; Cresto et al., 2019; Risher et al., 2018;
Risher et al., 2014). Astrocytes are able to mediate both excitatory (Christopherson et al., 2005)
and inhibitory synaptogenesis (Elmariah et al., 2005; A. Q. Nguyen et al., 2020) as well as
mediate synapse elimination via phagocytosis involving cell surface receptors such as MEGF10
and MERTK (Chung et al., 2013). Astrocytes promote synaptogenesis between developing
neurons by secreting a number of different factors (Allen et al., 2012; Baldwin & Eroglu, 2017;
Kucukdereli et al., 2011), including a class of extracellular matrix glycoproteins known as
thrombospondins (TSPs) (Christopherson et al., 2005; Risher & Eroglu, 2012). Of greatest
interest are thrombospondin 1 and 2 (TSP-1/2), which exert their synaptogenic effect by binding
to α2δ-1, a subunit of L-type voltage-gated Ca2+ channels found on the surface of neurons at preand postsynaptic terminals throughout the CNS (Risher et al., 2018) (Figure 2). This was further
evidenced by the observation that the number of excitatory glutamatergic synapses and overall
dendritic spine maturity were both decreased in the cerebral cortices of transgenic α2δ-1
knockout (α2δ-1 KO) mice (Risher et al., 2018). Given the known involvement of astrocytes in
certain forms of neuronal dysfunction and neurodegenerative disease (Cresto et al., 2019;
Sidoryk-Wegrzynowicz et al., 2011; Zoghbi & Bear, 2012), the effect of opioids on the
modulation of astrocyte signaling, particularly astrocyte-mediated synaptogenesis, may explain
some of the developmental aberrations associated with prenatal opioid exposure.
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Opioid receptors (particularly MORs) have been confirmed on the surface of astrocytes
(Hauser et al., 1996; Nam et al., 2018; Stiene-Martin & Hauser, 1991), making these cells
susceptible to receptor-ligand interactions with both endogenous and exogenous opioids.
Morphine and other MOR agonists have been shown to inhibit astrocyte growth and
development by suppressing DNA synthesis in vitro (Hauser et al., 1996) and increase
expression of glial fibrillary acidic protein (GFAP), an indicator of reactivity, in astrocytes
(Beitner-Johnson et al., 1993). Opioids also appear to affect astrocyte-neuronal interactions, as
cultured immortalized rat astrocytes subjected to prolonged treatment with µ-opioid receptor
agonists, including morphine, showed decreased production of TSP-1 and 2 (Phamduong et al.,
2014) (Figure 2). These findings can be seen in vivo as well, since rat pups repeatedly injected
with morphine were shown to have decreased astrocyte expression of TSP-1 (Ikeda et al., 2010).
The importance of astrocytes in the development of opioid addiction is also evidenced by
morphine-treated mice that showed enhanced conditioned place preference, actively choosing to
spend more time in a chamber paired with morphine injections over a chamber paired with saline
injections, after receiving injections of astrocyte conditioned media into their brains (Narita et
al., 2006). Greater understanding of the role of astrocytes in maintaining excitatory/inhibitory
synaptic balance, coupled with increased awareness of the effects of drugs of abuse on astrocytes
during development, may facilitate novel insight into how neurological function may be
impacted in cases of early life drug exposure.
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Figure 2: The Tripartite Synapse and the Interactions Between Thrombospondins (TSP),
α2δ-1, and Gabapentin (GBP)
Astrocyte foot processes interact with pre- and post-synaptic terminals. Opioids and gabapentin
have been shown, in different ways, to interfere with normal release of TSPs and their interaction
with α2δ-1. Adapted from figure originally presented in review article by Baldwin and Eroglu
(Baldwin & Eroglu, 2017).
Effects of Prenatal Gabapentin Exposure
Although the rise in rates of NAS over the past 20 years can largely be correlated with
the rise in rates of OUD, opioids are not the only class of drugs commonly used by women
during pregnancy. Co-abuse of multiple substances at once is common in these women and in
substance use disorder patients in general (Ahmad et al., 2022; O’Donnell J, 2020). One
prescription drug that has been shown to be increasingly co-abused along with opioids is
gabapentin, an anticonvulsant drug commonly prescribed for the treatment of neuropathic pain
14

(Smith et al., 2016). Originally prescribed to treat partial seizures, gabapentin has been
increasingly prescribed to treat neuropathic pain. Though originally designed as a structural
analogue for the neurotransmitter γ-aminobutyric acid (GABA), gabapentin does not bind to
GABAA or GABAB receptors. It has instead been proposed that gabapentin decreases
neurotransmitter release from the presynaptic terminal by inhibiting Ca2+ influx through L-type
channels (Fink et al., 2000; Patel & Dickenson, 2016). Although gabapentin was initially
believed to have no potential for abuse or addiction (Bastiaens et al., 2016; Smith et al., 2016),
surveys of OUD patients have found that as many as 26% of those interviewed reported abusing
gabapentin for nonmedical reasons, often taking gabapentin in combination with opioids as a
means to potentiate the experienced high (Baird et al., 2014; Bastiaens et al., 2016; Smith et al.,
2016). Supporting their testimonies are studies demonstrating that gabapentin has also been
shown to enhance the analgesia of morphine in a rat model (Meymandi et al., 2006). In addition,
clinicians have observed a unique presentation of NAS in infants whose mothers abused both
opioids and gabapentin while pregnant, with symptoms including tongue thrusting, back arching,
and increased eye wandering (Loudin et al., 2017). Reports of gabapentin’s potential for abuse
has led many states to classify the drug as a Schedule V Controlled Substance. The mechanisms
by which gabapentin and opioids may interact and the reasons for the unique presentation of
NAS in infants with a history of exposure to a combination of both drugs remain unclear.
A possible explanation for the unique interaction between gabapentin and opioids in
prenatally exposed infants may lie in the mechanism of action of gabapentin. Gabapentin is
believed to primarily act through binding to α2δ-1, the same Ca2+ channel subunit that, as stated
earlier, is also the binding site for TSP-1 and TSP-2 (Cole et al., 2005; Field et al., 2006; Nicolas
S. Gee, 1996). Gabapentin appears to interfere with TSP binding to α2δ-1 as evidenced by the
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disruption of normal astrocyte-induced synaptogenesis in cultured retinal ganglion cells in
response to the addition of gabapentin (Eroglu et al., 2009). This interference in normal
synaptogenesis could potentially explain the unique NAS phenotype associated with gabapentin
and could indicate the potential for greater disruption of neurological development.
Changes in Size and Structure in the CNS Associated with Prenatal Drug Exposure
The changes in cellular function and development observed to result from exposure to
drugs of abuse, particularly opioids and gabapentin, would be expected to be accompanied by
observable changes in the size, structure, and function of both the entire CNS as a whole and of
specific brain regions and the pathways that connect them. Within the brains of adults with a
history of long term prescription opioid dependence, Magnetic Resonance Imaging (MRI) scans
showed significant changes in functional connectivity have been observed, with the duration of
opioid exposure positively correlated with the severity of those changes (Upadhyay et al., 2010).
Additional MRI studies have shown reduced white matter and grey matter within the brains of
adult opioid abusers (Upadhyay et al., 2010; Y. Yuan et al., 2009).
In comparison to the changes observed in the adult CNS in response to opioid exposure,
prenatal opioid exposure tends to lead to even more dramatic effects. For decades, researchers
have observed lower birth weights and smaller head circumferences in children prenatally
exposed to opioids (H. Johnson et al., 1984; Asher Ornoy et al., 2001; Wilson et al., 1979).
These low birth weights in children correlate with higher rates of mortality in the first two years
of life (Ostrea et al., 1997) and have also been associated with poor performance in school and
higher rates of behavioral problems (McCormick et al., 1990; Taylor et al., 2015).
Other structural deficits associated with prenatal opioids have been observed in studies
utilizing medical imaging. Ultrasound studies have found that fetuses at 18-22 weeks gestation
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whose mothers were undergoing methadone maintenance therapy had significantly larger
thalamic diameter-to-head circumference ratios compared to a control group (Schulson et al.,
2014). Another ultrasound study observed abnormally small, slit-like ventricles in NAS affected
1-month-old infants (Pasto et al., 1985). Other studies utilized MRI to examine the brains of
children with a history of prenatal drug exposure. In both infants (Q. Yuan et al., 2014) and in
children 10-14 years of age (Sirnes et al., 2017), certain brain regions (including the basal
ganglia, thalamus, and cerebellar white matter) were observed to be significantly smaller
compared to age-matched control children after adjusting for intracranial volume and
birthweight. Another MRI study examining 17-22-year-olds whose mothers had abused multiple
drugs, including heroin, while pregnant had significantly smaller whole brain, cerebral cortex,
cerebral white matter, basal ganglia, pallidum, thalamus, and cerebellar white matter volumes
compared to controls (Egil Nygaard et al., 2018). Taken together, these results show that changes
in the sizes of brain region observed in drug-exposed infants can and do persist into adolescence
and young adulthood.
Prenatal Drug Exposure is Associated with Changes in Behavior
The types of changes observed within the CNS, both in cellular development and
systemic structure, could reasonably be expected to result in alterations to normal CNS function
that would be reflected in behavior. Indeed, a variety of behavioral and cognitive deficits have
been documented both in animal models of prenatal drug exposure and in human patients. Tests
of anxiety-type behaviors in animal models have shown significant differences between drugexposed and control subjects. Adult rats whose mothers were injected with morphine during
pregnancy were shown to spend less time both in the light compartment of a light/dark box and
while exploring the open arms of an elevated plus maze compared to rats whose mothers
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received saline (Ahmadalipour et al., 2015; Klausz et al., 2011). Similar behaviors suggestive of
more pronounced anxious phenotypes among these prenatal morphine-exposed rats were also
observed in rats prenatally exposed to buprenorphine (Chen H, 2015). Exactly what structural
and functional changes within the CNS would result in such anxious phenotypes have not yet
been determined.
Given the importance of opioids in reward processing, it is not surprising that rewardseeking and depressive behaviors are affected in animals prenatally exposed to opioids. Adult
rats exposed to morphine in utero showed a greater preference for a saccharin/water solution
over pure water compared to control rats, indicating an elevated response to pleasurable stimuli
(Gagin et al., 1996). Differences are also seen in exposed animals when faced with unpleasant
stimuli. Rats prenatally exposed to buprenorphine and tested using the forced swimming and tail
suspension tests showed reduced escape-oriented behaviors, which was interpreted as greater
depressive behavior than control rats (Hung et al., 2013; Wu et al., 2014) Changes in
connectivity or strength of the mesolimbic dopamine reward pathway caused by prenatal
exposure to opioids could explain these trends of elevated response to rewarding stimuli and
greater depressive behavior in response to unpleasant stimuli.
Studies utilizing memory tests have shown significantly worse performance in rodents
prenatally exposed to opioids compared to control animals. Rats prenatally exposed to morphine,
methadone, or buprenorphine subjected to tests of novel object recognition on postnatal day 44
were shown to have impaired recognition memory compared to control rats (Chen H, 2015).
When tested with the Morris water maze on postnatal day 30, rats prenatally exposed to heroin
took longer than unexposed rats to follow visual cues and swim to a platform they had previously
located, indicating deficits in learning and memory (Wang & Han, 2009). Another study showed
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a reduced tendency to explore a familiar object after it was moved to a novel location in 120day-old mice that had been exposed to heroin during prenatal development (Lu et al., 2012).
Studies use a variety of scales and tests to evaluate human cognitive function at different
developmental stages. The meta-analysis by Yeoh et al. (2019) of 26 human prenatal opioid
exposure studies provides an extensive overview of the current knowledge concerning cognitive
as well as motor related dysfunctions. Male infants with a history of prenatal opioid exposure
have been shown to score higher than females on tests of habituation, which measure the ability
of the infant to ignore extraneous environmental stimuli (Jones et al., 2010). One of the earliest
studies to investigate prenatal drug exposure in humans showed that children aged 3 to 6 years
old who were prenatally exposed to heroin performed worse on the General Cognitive Index and
on the perceptual performance, quantitative, and memory subtests of the McCarthy Scales of
Children’s Abilities (Wilson et al., 1979). Another study compared a group of 12-month-old
children with a history of prenatal methadone exposure to an age-matched control group by
utilizing the Bayley Scales of Infant Development. It was found that 20% of the methadoneexposed group had Mental Development Index scores indicative of developmental delay, while
only 4% of the unexposed children had such low scores (H. Johnson et al., 1984). A more recent
study used the second edition of the Bayley Scales of Infant Development (Bayley-II) to evaluate
a group of boys whose mothers had abused multiple drugs, including heroin, during pregnancy.
The average scores for these children at years 1, 2, and 3 were, respectively, 9.7, 12.9, and 10.3
points lower than the average scores for an unexposed control group (Egil Nygaard et al., 2015).
The same cohort scored 15.4 points lower than controls on the McCarthy Scales of Children's
Abilities at age 4.5 and 14.8 points lower than controls on the Wechsler Intelligence Scale for
Children at age 8.5, suggesting that diminished cognitive ability among prenatally the exposed
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children did not improve over time. An analysis of standardized test scores in New South Wales,
Australia also provides evidence that prenatally exposed children do not catch up with nonexposed peers in terms of cognitive ability. A cohort of children who had been diagnosed with
NAS as infants scored lower on the National Assessment Program: Literacy and Numeracy
(NAPLAN) than the statewide average and were more likely to not meet a minimum standard
score in grades 3, 5, and 7 (ages 8–9, 10–11, and 12–13 years respectively) (Oei et al., 2017).
These persistent trends imply that opioid exposure in early stages of development lead to lasting,
detrimental cognitive changes.
While standardized tests can be used to reveal deficits in cognitive function associated
with prenatal drug exposure, in some cases this exposure appears to negatively impact cognition
to the point where the affected child develops a diagnosable disability. A study in Tennessee
found that a group of school aged children (ages 3-8 years) with a history of NAS were more
likely to have been evaluated for, diagnosed with, or treated for an educational disability
compared to an age-matched control group of children (Fill et al., 2018). The authors of this
study also noted that children in the NAS group were more likely to have required specialized
classroom therapies or services than members of the control group. Another study used the
Truven Health Analytics’ Multi-State Medicaid Database to follow the psychiatric outcomes of
over 1,000 children who had been diagnosed with NAS as infants. Within their first 5 years of
life, these children were more than twice as likely to have been diagnosed with either disturbance
of conduct, hyperkinetic syndrome of childhood, adjustment reaction disorder, or an intellectual
disability compared to children with no history of NAS (Laura J. Sherman et al., 2019). Given
the increasing rates of NAS nationwide, observations such as these highlight the importance of
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research to an educational system that will have to accommodate the specific needs of the
affected children.
The vast majority of studies comparing cognitive function and mental health between
individuals with a history of prenatal drug exposure to non-exposed controls are focused on
children and adolescents. The number of longitudinal studies following subjects into adulthood is
limited. One study that included adult subjects examined a group of individuals 17-21 years of
age whose mothers had abused heroin and other drugs during pregnancy. It was found that
members of the prenatal drug-exposed group had significantly higher rates of attention deficit
disorder/attention hyperactivity disorder (ADD/ADHD) and substance abuse disorder compared
to a non-exposed age-matched control group (E. Nygaard et al., 2017). In addition, the exposed
group performed significantly poorer on tests of general mental abilities and memory compared
to the non-exposed control group (E. Nygaard et al., 2017).
Goals of this Dissertation
The combined results of these basic and clinical research studies, including my own study
identifying significant trends among a local population of NAS patients, appear to indicate that
there is an interaction between drugs of abuse, such as opioids and gabapentin, and astrocytemediated synaptogenic signaling. This interaction, predominantly centering on the association
between astrocyte-secreted thrombospondin and α2δ-1 expressed on the cell surface of neurons
at synaptic terminals, may be crucial to understanding the long-term effects of prenatal exposure
to drugs of abuse. With this in mind, two specific aims were developed for this dissertation: 1.
To test the hypothesis that exposure to opioids, gabapentin, or a polysubstance combination of
the two drugs during early life development will lead to significant disruptions in astrocyteregulated synaptic connectivity in brain regions associated with addiction and reward, and 2. To
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test the hypothesis that such drug-exposed mice would demonstrate more pronounced addictionrelated behavioral phenotypes compared to genetically similar drug-naïve mice.
To these aims, pregnant mice belonging to two separate lines transgenic for the
expression of α2δ-1 were administered one of four treatments: the opioid drug buprenorphine,
gabapentin, a combination of both drugs, or a vehicle control. α2δ-1 wild-type, heterozygous,
and knockout littermate pups of both sexes at 21 days of age were used for studies involving
immunohistochemistry and confocal fluorescence microscopy to determine the number of
synapses within brain regions associated with reward. A second cohort of transgenic pups at 70
days of age was subjected to a regimen of experiments meant to assess anxiety, impulsivity, and
reward-seeking type behaviors. By completing these studies, I hoped to contribute to a greater
understanding of the effects of prenatal opioid exposure on neurological and behavioral
development that would inform parents, healthcare providers, and educators looking to meet the
unique developmental and educational needs of children impacted by drug abuse.
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CHAPTER 2
AN INVESTIGATION INTO POTENTIAL TRENDS AMONG A LOCAL
POPULATION OF NEONATAL ABSTINENCE SYNDROME PATIENTS
INTRODUCTION
West Virginia has been especially negatively impacted by rising rates of opioid abuse and
neonatal abstinence syndrome (NAS) in recent years. The state routinely ranks among the
highest in the country in terms of NAS diagnoses (AHRQ, 2021; CDC, 2020; Hayes & Brown,
2012; Scholl L, 2019; Umer et al., 2019). Historically, patients living in rural regions such as
Appalachia have limited access to healthcare facilities and are therefore less likely to receive
treatment for substance abuse or NAS (J. Brown et al., 2018; Hayes & Brown, 2012). Lily’s
Place, a non-profit NAS treatment center in Huntington, WV, founded in 2014, provides
therapeutic and pharmacological care to newborns born at nearby hospitals diagnosed with NAS.
Patient records from facilities such as Lily’s Place may offer insight into the patient populations
that benefit most from the services provided by these facilities. In this study, the charts of
patients treated at Lily’s Place who returned for follow-up appointments between 2015 and 2019
were reviewed in order to examine any emerging trends among the children and their mothers.
The types of drugs abused by the mothers of patients, the number of patients to reach
developmental milestones, the types of medical issues observed among patients and their
mothers, the insurance status of the patients, and the plan for care at each patient appointment
were all recorded and compiled in order to report any emerging trends and increase
understanding of the patient population served by Lily’s Place. The results described in this
study are currently pending publication in the Journal of Clinical Pediatrics and Neonatology.
MATERIALS AND METHODS

23

Newborn patients from Huntington-area hospitals evaluated as showing symptoms of
NAS were referred and transported to Lily’s Place. During their stay at the facility each patient
was treated in individual nursery rooms where their health was monitored. Pharmaceutical
treatments, such as buprenorphine and/or clonidine, were administered to patients, if necessary,
to help mitigate the process of weaning them from drugs of abuse. A monthly follow-up clinic
was held for the parents of patients to bring their children for neurological and general health
evaluations. The first follow-up appointments for all patients are scheduled 3 months following
departure from the treatment center. Electronic charts (Allscripts Healthcare, LLC, Chicago, IL)
from Lily’s Place patients who appeared for these follow-up visits between the years 2015 to
2019 were compiled and analyzed using statistical software (Microsoft Excel, Redmond,
WA and GraphPad Prism, San Diego, CA). Confidentiality of patient names and identifying
information was maintained in line with HIPAA regulations.
RESULTS
Few Patients Returned for More than One Follow-Up Appointment
One hundred and twenty-two patients who appeared for follow-up appointments at Lily’s
Place between 2015 and 2019 were included in this study. These patients accounted for a total of
217 individual clinic visits. Of the 122 patients who appeared for follow-up appointments at
Lily’s Place, 64 (52.5%) were male and 58 (47.5%) were female. Fifteen patients were born via
cesarian section while seven were born prematurely (before 37 weeks of pregnancy).
The majority of patients appeared at the clinic only once (67 patients or 54.9%), despite
the encouragement for parents to schedule additional appointments (Figure 3). The mean
number of visits per patient was 1.92 with the highest number of visits for any one patient being
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9. Seventy-five patients arrived in the custody of someone other than a biological parent, such as
foster parents or grandparents, at the time of their follow-up appointment.

Figure 3: Patient Appearance for Follow-Up Appointments
Breakdown of the numbers of times patients appeared for follow-up appointments at Lily’s Place
in Huntington, WV.
Certain Drugs Were Commonly Misused by Patient Mothers
Drugs of abuse taken by the mothers of patients during their pregnancies were reported in
the patient records through a combination of drug screenings at the time of birth or through selfreport by the mothers (see Table 1). Opioid drugs of some form were confirmed to be used by
104 mothers of patients (85.2%) during their pregnancy. The single most commonly used drug
among mothers of patients was buprenorphine, with 56 either currently taking the drug as a part
of medication-assisted treatment for opioid abuse or with a history of using the drug without a
prescription. 28 mothers were recorded as having used heroin. Tobacco products were the most
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commonly used non-opioid drugs (31 mothers; 25.4%) followed by cannabis products and
gabapentinoids (e.g. Neurontin®, Lyrica®) with 19 mothers (15.6%) each.

Drug
Some Form of Opioid
Methadone
Buprenorphine
Heroin
Unknown/Other
Tobacco
Cocaine
Benzodiazepine
Methamphetamine
Cannabis/THC
Gabapentinoids
Alcohol
SSRIs
TCAs
Tramadol
Other

# Patient Mothers
104
26
56
28
39
31
11
14
7
19
19
2
8
2
2
6

Table 1: Drugs Misused by the Mothers of Patients During Their Pregnancies

Many Patients Did Not Reach Developmental Milestones on Time
The development of each patient was assessed in each follow-up appointment based on
the Centers for Disease Control and Prevention’s (CDC) Developmental Milestones, a list of
motor skills and behaviors that indicate typical normal and healthy development in young
children ("CDC’s developmental milestones," 2020). The milestones are separated into four
categories: Social/Emotional, Language/Communication, Cognitive Milestones (learning,
thinking, problem-solving), and Movement/Physical Development Milestones. The number of
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patients to reach all milestones assigned for their age group was recorded for this study (Table
2). By two months of age, infants are expected to be able to perform such tasks as hold their head
up when on lying on their stomach, move both arms and both legs, follow movement with their
eyes, and smile in response to words or smiling faces. Only 17 of the 122 patients included in
this study successfully reached all these developmental milestones at two months of age. At four
months of age, milestones for infants include being able to hold their head steady without
support when being held, hold a toy in their hands, bring their hands to their mouth, turn their
head to follow the sound of a voice, and push up onto elbows/forearms when on stomach. Only
14 patients in this study managed to reach all of these developmental milestones on time.
Milestones for an infant at 6 months of age include being able to recognize familiar people, reach
to grab objects and place them in their mouth, make squealing noises, and push themselves up
with their arms and roll over to their backs when lying on their stomachs. Only seven patients
successfully reached all these developmental milestones at the designated age. These results
reflect significant developmental delays among this population of NAS patients, and likely
among NAS patients in general.

Developmental Milestone Age (months)

# Patients

2
4
6
9
12
18

17
14
7
5
6
1

Table 2: Number of Patients Who Reached Each CDC Developmental Milestone
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Certain Medical Issues Were Frequently Observed Among the Patients
Medical issues commonly observed among Lily’s Place patients during their follow-up
appointments were recorded (see Table 3). The most common medical issues seen in patients
were musculoskeletal, with 47 patients (38.5%) showing muscle and/or joint tightness, most
commonly within the hips and legs. Twenty patients were diagnosed with torticollis and 10
showed muscle weakness or low tone in at least one major muscle group.
In terms of neurological symptoms, 38 patients (31.1%) exhibited tremors that could not
be attributed to another neurological condition during their appointments. Among these patients,
25 patients exhibited tremors at their 3-month follow-up but not in subsequent clinic visits. The
latest any patient demonstrated tremors during an examination was at 8 months of age. In
addition, 6 patients exhibited clonus in at least one heel when tested during their neurological
examinations.
The most common medical issue not involving the musculoskeletal or nervous systems
was gastroesophageal reflux disease (GERD) with 40 patients diagnosed with the condition, the
majority of which also had already been prescribed ranitidine (Zantac®) to reduce reflux by their
primary care physicians. Five patients were diagnosed with asthma and had all been prescribed
medications for its treatment.
Certain Medical Issues Were Common Among the Mothers of Patients
Significant health conditions of the mothers of patients were included in their children’s
medical histories if such a condition could have impacted either their pregnancy or the delivery
(see Table 4). The most common medical condition among mothers was Hepatitis C. Forty-three
mothers either tested positive at the time of delivery or had a recent history of testing positive.
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Sexually transmitted diseases, hypertension, diabetes, and psychological conditions (including
depression, anxiety, and bipolar disorder) were also observed in mothers.

Medical Issue
Muscle/Joint Tightness
G.E.R.D.
Tremors
Torticollis
Low tone/muscle
weakness
Clonus
Asthma

# Patients
47
40
38
20
10
6
5

Table 3: Common Medical Issues Observed Among Lily’s Place Patients at Follow-Up
Appointments
(G.E.R.D.: gastroesophageal reflux disease)

Medical Issue
Hepatitis C
Herpes Simplex
Other STD
Hypertension
Psychological Disorder
Diabetes

# Patient Mothers
43
4
3
4
3
2

Table 4: Common Medical Diagnoses Among the Mothers of Lily’s Place Patients

Medicaid was Primary Medical Insurance for Majority of Patients
The medical insurance status of each patient was recorded at each clinic visit. Primary
medical insurance for 65 patients (53.3%) was listed as West Virginia Medicaid, making it the
most common form of insurance among the patients included in this study. Ten patients had no
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medical insurance or were listed as “Self-pay” at the time of their appointment. All other patients
were insured by at least one other healthcare insurance company (e.g. Aetna®).
A Plan for Care was Developed to Meet the Needs of Each Patient
At the end of every patient encounter, in addition to scheduling their next appointment at
the clinic, a plan was developed to attempt to meet the medical needs of each patient. Sixty-six
of 217 visits to Lily’s Place resulted in a referral to developmental support services such as Birth
to Three (BTT), a program developed by the West Virginia Department of Health and Human
Resources (DHHR) through the Bureau for Public Health and the Office of Maternal, Child, and
Family Health available for free to all children at risk for a developmental delay. Other services
to which patients were referred included Head Start (a program overseen by the United States
DHHR Office of the Administration for Children & Families), First Steps (overseen by the
Kentucky Department for Public Health in the Cabinet for Health and Family Services), or one
of Cabell Huntington Hospital’s Rehabilitation Services (including physical therapy,
occupational therapy, and speech therapy). Sixty-one clinic visits included a demonstration of
stretches or exercises designed to improve muscle/joint tightness or low tone/muscle weakness.
Specific recommendations other than stretching or exercise, such as increasing the amount of
time the patient spent on its stomach to promote motor skills or deliberately stimulating one side
of the patient’s face in order to encourage head turning in a specific direction to treat torticollis,
were made in 13 visits. In 11 visits, specific physical aids, such as supportive shoes, were
encouraged to improve mobility development in struggling patients. Tests such as MRI scans or
prescription drugs were ordered in only seven patient visits. Discussions of test results or general
reassurance of patient parents/guardians occurred in 13 visits, while in 20 visits
parents/guardians of patients were given encouragement to continue current therapies with the
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goal of reaching developmental milestones. At the end of 13 separate visits, plans were made to
consult with additional physician(s) (such as the patient’s primary care physician) to discuss a
patient’s plan for treatment. Lastly, although written informational materials are always made
available to patients and their families, during two separate interactions relevant informational
handouts were shared and discussed with the patient’s parents/guardians

Plan For Care at Visit
Encourage Developmental Milestones
Referral to Birth to 3, First Steps, PT, etc.
Reassurance or Discussion of Test Results
Specific Recommendation (Tummy time,
stimulation of one side of face, etc.)
Prescription or Test Ordered (e.g. MRI)
Demonstrated Stretching or Exercises
Recommended Shoes or Other Physical Aid
Device
Consult with Other Physician
Handout or Written Information Handed Out

# Appointments
20
66
13
13
7
61
11
13
2

Table 5: Plans for Care Developed for Patients at the End of Follow-Up Appointments

DISCUSSION
The results of this study of NAS patients treated at Lily’s Place reveal some important
information about trends among NAS patients in West Virginia and, potentially, in the wider
United States. The high appearance of opioid drug use among the mothers of patients is
consistent with national trends of increased rates of opioid (Hedegaard H., 2020; Scholl L, 2019;
USDHHS, 2015) abuse. The long-term health and psychological effects of prenatal exposure to
drugs of abuse, such as opioids, continue to be an area of intense scientific investigation. Many
such studies suggest a correlation between prenatal drug exposure and diagnosis of an
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intellectual disability or mental disorder (Fill et al., 2018; H. Johnson et al., 1984; Laura J.
Sherman et al., 2019; Egil Nygaard et al., 2015; Egil Nygaard et al., 2018; A. Ornoy, 2003; Ross
et al., 2015; Sirnes et al., 2017). Additional studies suggest a correlation between prenatal drug
exposure and poor academic performance (Fill et al.; Oei et al., 2017).
Among the opioid drugs used by patients, the single most common drug was
buprenorphine. Buprenorphine is increasingly prescribed to pregnant mothers as part of
medication-assisted therapy to help them overcome opioid addiction and limit the exposure of
the developing fetus to potentially more harmful opioids (Jansson & Velez, 2012). It has also
been prescribed as a weaning therapeutic in place of methadone for infants with NAS prenatally
exposed to opioids (Kraft, 2018). Therefore, it is not surprising that the most common drug taken
by the mothers of the children in this study was some form of buprenorphine (as Subutex®,
Suboxone®, Butrans®, etc.). However, this study agrees with previous research which shows
that buprenorphine as a replacement therapy for other opioids does not eliminate the risk of NAS
in exposed infants (Kayemba-Kay’s & Laclyde, 2003; Kraft, 2018). Of the six patients included
in this study that exhibited clonus, five had been exposed to buprenorphine in utero (the 6th was
exposed to methadone and other unspecified opioid drugs), a possible indication that a greater
understanding of the effects of prenatal exposure to opioids, even ones considered “less harmful”
such as buprenorphine, is still needed.
Drugs besides opioids were also observed in significant numbers among the mothers of
NAS patients. Tobacco products were found to be the second most common drugs of abuse.
Products containing nicotine, including cigarettes or electronic vape devices are commonly used
by OUD patients, and the cessation of such products is not often encouraged in patients
undergoing opioid abuse treatment programs (Guydish et al., 2011). Gabapentinoids such as
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gabapentin have increasingly been reported as being misused by substance abuse patients
(Vickers Smith et al., 2018), both the drugs by themselves and in combination with opioids in
order to potentiate the experienced high (Bastiaens et al., 2016). A unique set of NAS symptoms,
such as tongue thrusting, back arching, and eye wandering, have also been reported among
infants who were prenatally exposed to gabapentinoids (Loudin et al., 2017). Although the rise in
rates of abuse of opioids is likely the driving factor for the rise in rates of NAS, these drugs of
abuse are not the only ones commonly used by pregnant women and are often co-abused with
other non-opioids.
Among the medical conditions observed among the patients, musculoskeletal issues were
among the most common. The high rate of muscle and joint tightness seen among these patients
can likely be attributed to the care they received during their initial stay at Lily’s Place. Tightly
wrapping the body of an infant suffering from NAS in blankets has been shown to be an
effective method of soothing these frequently fussy patients (Blount et al., 2019). This swaddling
keeps the limbs of the infant immobile and close to its body, potentially resulting in muscle and
joint tightness that must be remedied by stretching later in the child’s development to avoid long
term difficulties.
Examining the different plans for care developed in each appointment also gives insight
into the different needs of the patients served by Lily’s Place. A large number of patient
interactions involved only reassurance, guidance, or counseling on the part of the physician.
Some of the most common issues seen among this patient group, namely muscle/joint stiffness,
torticollis, and low tone/muscle weakness, could in fact be remedied through exercises, stretches,
and specific recommendations (e.g. stimulating one side of the patient’s face to promote head
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turning) designed to promote musculoskeletal development (Carenzio et al., 2015; He et al.,
2017).
This study also revealed important demographic information about patients most likely to
receive services from facilities such as Lily’s Place. Over half of all patients included in this
study were insured by Medicaid, indicating that the majority of patients seen at Lily’s Place
could likely be described as lower socio-economic status. While substance abuse and socioeconomic status are not necessarily correlated (Hanson & Chen, 2007; M. Patrick et al., 2012),
families of a lower socio-economic status traditionally have limited access to quality healthcare
(Becker & Newsom, 2003; Braveman & Gottlieb, 2014) and children of such families tend to do
worse in academic settings (Thomson, 2018). In addition, the majority of patients in this study
appeared at their follow-up appointments in the legal custody of someone other than their
biological mothers. Stressful early life events and environments, such as those that might be
found during a transition between biological and foster parent care, are correlated with poorer
cognitive and physical development in children (Berry et al., 2016; Coley et al., 2015). Such
considerations may make a significant difference for NAS patients who would benefit from the
involvement of social welfare programs as well as the engagement of invested healthcare
professionals.
While this study was successful in its attempts to describe trends observed among the
chosen group of patients, there are several important limitations of this investigation that need to
be considered. Given how many infants are diagnosed with NAS each year (AHRQ, 2021), this
pool of 122 patients may be too small to accurately represent the tens of thousands of NAS
patients currently living in the United States. In addition, while this study was primarily a review
of the charts of patients diagnosed with NAS, the full medical histories of the mothers of these
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patients were not reviewed. Only pertinent information concerning disease status and drug abuse
history that was gained through interviews and examinations of mothers after they had been
admitted to the hospital in the lead up to delivery was included in this study. Any demographical
information concerning such factors as race or socio-economic status was also not included in
this study in the interest of maintaining patient anonymity. Gathering this type of information
may have revealed information about the circumstances of women most likely to give birth to
children diagnosed with NAS. Additional outreach and prenatal care could be beneficial to such
women and may even assist them in treating their substance use, thus lowering the risk of their
children developing NAS. Future studies of similar patient populations may benefit from
including a greater number of patient records from a wider geographical area as well as including
information from the health histories of the mothers of the patients.
The results of this study may point towards important trends among NAS patients and
their families in West Virginia and, potentially, in the wider United States. The data gained from
this study should make apparent the importance of regular medical evaluation in the months
immediately following treatment for NAS. It should also make apparent the need for facilities
such as Lily’s Place that seek to meet the healthcare needs of socio-economically disadvantaged
populations. Increased understanding of the patient population served by a healthcare facility is
likely to result in better patient outcomes and shape future policy to provide services better
designed to meet the needs of those patients.
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CHAPTER 3
AN INVESTIGATION OF ALTERATIONS IN SYNAPTIC DEVELOPMENT IN A
MOUSE MODEL OF EARLY LIFE DRUG EXPOSURE
INTRODUCTION
Despite considerable research efforts to increase the understanding of the
pathophysiology of NAS as well as methods to improve treatment of NAS symptoms (Bio et al.,
2011; Grossman & Berkwitt, 2019; Jansson & Velez, 2012; Kocherlakota, 2014; Patrick et al.,
2014), knowledge concerning the long-term effects of prenatal exposure to drugs of abuse on
neurological development is limited (Boggess & Risher, 2020). One of the most commonly used
opioid drugs among pregnant substance abuse patients is buprenorphine, a partial MOR agonist
that is often prescribed to replace and prevent the reinforcing effects of more harmful and
addictive opioid drugs, such as heroin or fentanyl. Buprenorphine is often used in medicationassisted treatment (MAT) to help treat OUD in pregnant women in the hopes of achieving better
health outcomes for the mother and child. However, emerging evidence asserts that any opioid
use during pregnancy, even when part of a medical treatment plan, can have deleterious effects
on the developing fetus (Burke & Beckwith, 2017; Kayemba-Kay’s & Laclyde, 2003).
While the increased prevalence of opioid abuse is often credited with the rise in incidence
of NAS, it is important to note that many mothers of NAS patients abuse multiple drugs besides,
or in combination with, opioids. One prescription drug that has been shown to be increasingly
co-abused along with opioids is gabapentin (Smith et al., 2016). OUD patients have reported
abusing gabapentin in combination with opioids as a means to potentiate the experienced high
(Baird et al., 2014; Bastiaens et al., 2016; Smith et al., 2016). In addition, clinicians have
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observed a unique presentation of NAS in infants whose mothers abused both opioids and
gabapentin while pregnant (Loudin et al., 2017).
Although the mechanisms by which gabapentin and opioids may interact with each other
are unknown, the addictive nature of such drugs of abuse can largely be attributed to their
activity within the mesolimbic dopamine pathway (Figure 1) (Carlezon & Wise, 1996; Di Chiara
et al., 2004; Wachtel et al., 1989). Examining the effects of these drugs of abuse on
synaptogenesis within brain regions associated with the mesolimbic dopamine pathway may lead
to insight on how these drugs affect neurological development in prenatally exposed children.
In this study, we used fluorescence immunohistochemistry (IHC) in a mouse model of
early life drug exposure to investigate the effects of both buprenorphine and gabapentin on
developmental synaptic connectivity. Our hypothesis was that exposure to buprenorphine,
gabapentin, or a combination of both drugs during critical periods for synaptic development
would lead to significant disruptions in excitatory and inhibitory synaptic connectivity in brain
regions associated with addiction and reward. We further hypothesized that haploinsufficiency of
the calcium channel subunit α2δ-1, the receptor for gabapentin and a critical player in
developmental synapse formation and maturation, would result in further disruption of these
synaptic populations. The results described in this study were previously published in Frontiers
in Pediatrics (Boggess et al., 2021).

MATERIALS AND METHODS
Animals and Drug Treatments
All experiments were conducted in accordance with Marshall University’s Institutional
Animal Care and Use Committee (IACUC) guidelines (W.C.R. protocols 696 and 697). Adult
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C57Bl/6J mice heterozygous for Cacna2d1, the gene encoding α2δ-1 (i.e. α2δ-1 +/-) (Risher et
al., 2018) were a kind gift from Dr. Cagla Eroglu (Duke University). The mice were bred onsite
at the Marshall University Animal Resource Facility. Virgin α2δ-1 +/- females and α2δ-1 +/males were set up as mating pairs. Visual confirmation of a vaginal plug was counted as
embryonic day 0 (E0) at which time males and females were separated. On E6, pregnant females
were given access to 1 ml of a 1:1 sweetened condensed milk/water solution served in a plastic
35 mm dish. Starting on E7, pregnant females were given free access to a once daily 1 ml
solution of 1:1 condensed milk/water containing either pharmaceutical grade buprenorphine
hydrochloride (CIII) (5 mg/kg; Spectrum Chemical, Gardena, CA), gabapentin (30 mg/kg;
Spectrum), a combination of both drug doses, or vehicle control. These doses were selected
based on the results of previous rodent studies that used these drugs (Martin et al., 2001;
Meymandi et al., 2006). Drug doses were calculated based on the weight of pregnant females on
E7. Daily dosing continued through the birth of pups and ended on postnatal day 11 (P11). All
animals were given ad libitum food (standard mouse chow milled on site) and water.
For wild-type (WT) mice, seven pups (three male and four female) from vehicle control
treated litters, six (two male, four female) from gabapentin treated litters, six (three male, three
female) from buprenorphine treated litters, and seven (four male, three female) from combined
buprenorphine and gabapentin treated litters were included. For α2δ-1 +/- mice, 11 pups (five
male, six female) from vehicle control treated litters, seven (three male, four female) from
gabapentin treated litters, seven (four male, three female) from buprenorphine treated litters, and
seven (four male, three female) from combined buprenorphine and gabapentin treated litters
were included.
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Mouse Brain Sample Drug Concentration Analysis
The brains of newborn WT pups from dams treated with 5 mg/kg buprenorphine (six
pups), 30 mg/kg gabapentin (15 pups), or vehicle control (15 pups; two litters per treatment)
were isolated and then shipped on dry ice to the Pharmaceutical Sciences Research Institute at
the McWhorter School of Pharmacy (Samford University, Birmingham, AL) for drug
concentration analysis. Mouse brain samples were homogenized 1:5 with 5 mM ammonium
acetate buffer using an Omni THQ homogenizer (Atlanta, GA). Gabapentin calibration
standards, blanks and QCs were prepared by spiking 20 µl of blank control brain homogenate
with the appropriate amount of gabapentin to achieve concentrations in ranging from 25-10,000
ng/ml. Internal standard (1 ml of 100 ng/ml Gabapentin-d4 in methanol) was added to precipitate
the proteins. After centrifugation for five minutes at 13,000 rpm, the supernatant was transferred
to glass tubes and the solvent was evaporated under nitrogen at 40°C. The samples were then
redissolved in 200 µl of 95/5 10 mM ammonium formate/methanol with 0.1% formic acid and
transferred to limited volume autosampler vials and analyzed in positive ion mode by liquid
chromatography with tandem mass spectrometry (LC/MS/MS).
Buprenorphine calibration standards, blanks, and quality controls (QCs) were prepared by
spiking 100 µl of blank control brain homogenate with the appropriate amount of buprenorphine
to achieve concentrations ranging from 0.2-200 ng/ml. Standards, blanks, QCs and samples were
spiked with internal standard (10 µl of 50 ng/ml Terfenadine in acetonitrile). Acetonitrile (1 ml)
was added to precipitate the proteins. After centrifugation for five minutes at 13,000 rpm, the
supernatant was transferred to glass tubes and the solvent was evaporated under nitrogen at
50°C. The samples were then redissolved in 200 µl of 50/50 5 mM ammonium
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acetate/acetonitrile and transferred to limited volume autosampler vials and analyzed in positive
ion mode by LC/MS/MS.
The LC/MS/MS system consisted of Shimadzu system (Columbia, MD) equipped with
LC20-AD dual HLPC pumps, an SIL20-AC HT autosampler, and a DGU-20A2 in-line degasser.
Detection was performed using an Applied BioSystems 4000 QTRAP (Applied Biosystems,
Foster City, CA) triple quadrupole mass spectrometer operated in the positive ion mode utilizing
electrospray ionization. Mass calibration, data acquisition and quantitation were performed using
Applied Biosystem Analyst 1.6.2 software (Applied Biosystems).
Separation of gabapentin and the gabapentin-d4 from the brain homogenate matrix was
achieved from a 10 μl injection of the samples using a Phenomenex Polar C18, 100 X 2 mm 5
µm particle column. The mobile phase was delivered at a flow rate of 400 µl/min using a
gradient elution profile consisting of 5 mM ammonium acetate (A) and acetonitrile with 0.1%
formic acid (B). The analyte and internal standard were detected using multiple reaction
monitoring (MRM) for the following transitions: Gabapentin (m/z 172.2 à 137.0), Gabapentin-d4
(m/z 176.2 à 141.0).
Separation of buprenorphine and terfenadine from the brain homogenate matrix was
achieved from a 10 μl injection of the samples using a Phenomenex Luna C18, 100 X 2 mm 5
µm particle column. The mobile phase was delivered at a flow rate of 400 µl/min using a
gradient elution profile consisting of 5 mM ammonium acetate with 0.1% formic acid (A) and
acetonitrile with 0.1% formic acid (B). The analyte and internal standard were detected using
multiple reaction monitoring (MRM) for the following transitions: Buprenorphine (m/z 468.4 à
396.1), Terfenadine (m/z 472.4 à 436.3). Drug concentrations are summarized in Table 6.
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Genotyping
At P7, the tails of the pups were clipped and collected. Toe pads were tattooed (AIMS
NEO9 Animal Tattoo System, Hornell, NY) for later identification. Tissue digestion was
performed on the clipped tails and DNA was isolated for PCR amplification and genotyping with
a 2% agarose gel. Pups were identified as either α2δ-1 +/+ wildtype (WT), α2δ-1 +/heterozygous (Het), or α2δ-1 -/- knockout (KO) using the following primers: F1 (WT forward,
5′-TCTCAGTTACAAGACTATGTGG-3′), F3 (KO forward, 5′GGCTGTGTCCTTATTTATGG-3′), and LAF-Test (reverse, 5′AGTAGGAGAAGGTACAATCGGC-3′) (Integrated DNA Technologies, Coralville, IA).
Perfusion, Freezing, and Cryosectioning
For the P21 mouse group, when a litter reached P21, the dam and pups were placed
individually on a scale to be weighed (group data is included in Table 7) before being
anesthetized with tribromoethanol/Avertin (250 mg/kg). Cardiac perfusion was performed, first
with 0.24 μg/ml heparin salt in 0.1M phosphate buffered saline (PBS) for two minutes followed
by 4% paraformaldehyde (PFA) for two-five minutes at a flow rate of 5 ml/min. The brains of
the dam and pups were extracted and submerged in 4% PFA at 4°C for 24 hours. After 24 hours,
the brains were rinsed in PBS and then placed in 30% sucrose:PBS solution for 48 hours. Brains
were removed from sucrose solution, submerged in 2:1 sucrose solution:Tissue Freezing
Medium (Cat. #72592-G, Electron Microscopy Sciences), and frozen within plastic embedding
molds (Cat. #70182, Electron Microscopy Sciences, Hatfield, PA). All brains were stored at 80°C until they were cryosectioned into 20 μm slices using a Leica CM 1950 (Leica, Wetzlar,
Germany) and stored in 50% glycerol:Tris-Buffered Saline (TBS) at -20°C.
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Synaptic Labeling Immunohistochemistry
Three independent coronal sections per mouse containing the PFC (bregma, 2.96 to 2.58
mm; interaural, 6.76 to 6.38 mm) and three sections per mouse containing the ACC and NAC
core/shell (bregma, 1.42 to 0.86 mm; interaural, 5.22 to 4.66 mm) were used for analyses
(Paxinos, 2008). After selection, brain slices were washed in TBS + 0.2% Triton X-10% (Cat.
#11332481001, Roche Diagnostics, Mannheim, Germany) w/v (TBST) solution at room
temperature. The slices were then placed in a 5% normal goat serum (NGS; Cat. #005-000-121,
Jackson Immuno Research Laboratories Inc., West Grove, PA):TBST solution for 1 hour to
block nonspecific binding sites. After blocking was completed, the slices were then placed in 5%
NGS:TBST containing primary antibodies against both pre- and postsynaptic proteins. Guinea
pig anti-vesicular glutamate transporter 1 (VGluT1; Cat. #AB5905, EMD Millipore, Burlington,
MA) at 1:2000 dilution was used to identify excitatory glutamatergic presynaptic axonal regions
while rabbit anti-post synaptic density protein 95 (PSD95; Cat. #51-6900, Invitrogen, Carlsbad,
CA) at 1:300 dilution was used to identify postsynaptic dendritic regions. To label inhibitory
GABAergic synapses, guinea pig anti-vesicular GABA transporter (VGAT; Cat. #131004,
Synaptic Systems, Göttingen, Germany) at 1:1000 dilution was used to identify presynaptic
axonal regions and rabbit anti-gephyrin (Cat. #147002, Synaptic Systems) at 1:1000 dilution was
used to identify postsynaptic dendritic regions. Slices were incubated overnight on an orbital
shaker at 4°C.
After overnight incubation was completed, brain slices were removed from primary
antibody solution and washed with TBST. Slices were then placed in 5% NGS:TBST containing
fluorescent secondary antibodies against the primary antibodies. Alexa Fluor IgG (H+L) 594
goat anti-guinea pig (Cat. #A11076, Invitrogen, Carlsbad, CA) at 1:200 dilution was used to
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stain against presynaptic antibodies (either VGluT1 for excitatory or VGAT for inhibitory) and
Alexa Fluor IgG (H+L) 488 goat anti-rabbit (Cat. #A11034, Invitrogen) at 1:200 dilution was
used to stain against postsynaptic antibodies (either PSD95 for excitatory or gephyrin for
inhibitory). Slices were incubated for two hours at room temperature in darkness. After
incubation was complete, the slices were washed with TBST.
After the final washing step, the slices were rinsed once in 2/3 TBS:1/3 dH20 solution.
Then, the slices were transferred onto glass slides and excess liquid was suctioned off with a
pipette. One drop of mounting media containing DAPI (Cat. #H-1200; VectaShield, Burlingame,
CA) was applied to each slice prior to placement of coverslip and sealing with clear nail polish.
The glass slides were allowed to dry overnight in darkness before being stored at -20°C.
Confocal Fluorescence Microscopy for Synaptic Protein Imaging
Images of the slides were captured using the Leica SP5 Confocal Fluorescence
Microscope housed and maintained by the Marshall University Molecular Biological and
Imaging Core. Argon visible light laser (at 30% final filter power) was used with emission
windows set at 493 nm – 550 nm for blue excitation and 595 nm – 647 nm for green excitation.
Leica LAS AF software was used to capture 5 μm z-stacks with 15 steps (0.33μm distance
between each step) within the brain regions of interest (ROI) across all treatment groups (imaged
area/scan = 19,036 µm2; 63× oil objective, 1.4 NA) (Figure 1B-D).
Synaptic Puncta Image Analysis
The saved confocal images were analyzed using ImageJ (NIH) software. The custom
plug-in “ProjectZ_Triple” was used to average and convert the 15 separate images of each zstack into five separate maximum projections, each representing a 1 μm “mini-stack”. Puncta
Analyzer (Dr. Cagla Eroglu, Duke University, Durham, NC) was then used to quantify the
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number of discrete puncta for the 493 nm – 550 nm wavelength channel (corresponding to
PSD95 in brain slices stained for excitatory synapses or Gephyrin for inhibitory synapses), the
595 nm – 647 nm wavelength channel (corresponding to VGluT1 in brain slices stained for
excitatory synapses or VGAT for inhibitory synapses), and the co-localized puncta, where puncta
from both channels overlapped within four pixels of each other (Figure 4). These regions of colocalization of pre- and postsynaptic markers were designated as synapses (Ippolito & Eroglu,
2010). The counted synapses were compiled into spreadsheets (Microsoft Excel, Redmond, WA)
and analyzed with GraphPad Prism (San Diego, CA).
Statistical Analysis
For body mass comparisons, dams belonging to different treatment groups were
compared via One-Way ANOVA with Tukey’s multiple comparisons post hoc test. For pups, a
Three-Way ANOVA (treatment × genotype × sex) was performed with Tukey’s multiple
comparisons post hoc test. The D’Agostino and Pearson omnibus normality test confirmed that
most synapse counts were not normally distributed; therefore, statistical differences were
analyzed using the nonparametric Kruskal-Wallis test to detect differences in mean number of
synapses amongst drug treatments or between genotypes. Post-hoc Dunn’s multiple comparisons
tests were performed to detect significant differences (p<0.05) amongst the mean values of each
treatment group. Analyses were performed using GraphPad Prism.
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Figure 4: Visual Representation of Immunohistochemistry Staining
Representative images taken by confocal fluorescent microscope along with graphic
representations of pre- (green) and post-synaptic (red) terminals meeting at puncta of colocalization (yellow). (A) Representative example merged image of red and green channels with
arrows indicating colocalization. (B) Representative images for VGluT1 and PSD95 staining
with graphic representation of excitatory glutamatergic puncta. (C) Representative images for
VGAT and Gephyrin staining with graphic representation of inhibitory GABAergic puncta.
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RESULTS
Drug Accumulation was Confirmed in Neonatal Mouse Brain Tissue
From E7 until P11, pregnant C57Bl/6J mice were administered drug treatments within 1
ml of a 1:1 sweetened condensed milk/water solution. It is important to note here that since drug
treatments continued after the birth of pups and could therefore still be transferred from the dam
to the pups via the breast milk, the treatments included in these studies are described as “early
life” rather than “prenatal”. The plastic dishes in which those drug treatments were served were
consistently observed to be empty on the following day, confirming that the dams routinely
consumed the entirety of the treatment solution. Concentrations of buprenorphine and gabapentin
within the brains of adult rodents following administration have previously been demonstrated at
detectable levels (Errante & Petroff, 2003; Rudeck et al., 2020). To confirm drug passage from
dam to pups in this study, the brains of newborn pups from litters treated with buprenorphine,
gabapentin, or a vehicle control were isolated, lysed, and subjected to liquid chromatographytandem mass spectrometry to determine brain tissue concentrations for each drug. Both
buprenorphine and gabapentin were detected in the brains of the exposed pups (Table 6).

Drug Concentrations in Brain Tissue Lysates from Drug Exposed Pups
Pup:Maternal
Treatment
Maternal Dose
n
Concentration
Concentration Ratio
Buprenorphine
5 mg/kg
6
1.85 ± 0.30 nM
0.054 ± 0.009
Gabapentin
30 mg/kg
15
3.29 ± 0.84 μM
0.259 ± 0.037
Vehicle
0 mg/kg
15
0 μM (both drugs)
N/A

Table 6: Drug Concentrations (Shown as Mean ± SEM) Within Brain Tissue Lysates from
Drug-Exposed Newborn C57Bl/6/J Pups Determined via Liquid Chromatography-Tandem
Mass Spectrometry
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Body Mass of Dams and Pups Impacted by Drug Treatment, Sex, and Expression of α2δ-1
In order to produce the required number of WT and Het pups for IHC in this study, the
following litter numbers were required: four litters dosed with vehicle control, five litters dosed
with 30mg/kg gabapentin, four litters dosed with 5mg/kg buprenorphine, and five litters dosed
with both drugs. Immediately before anesthetization and perfusion at P21, dams and all pups
from each litter were weighed and their weights were recorded. The mean masses for the dams of
the different litters and the pups in each sex-genotype-treatment group were calculated (Table 7).
The mean body masses for dams revealed a significant main effect of treatment, [F(3, 14) =
50.21, p < 0.0001]. Dams treated with buprenorphine (p = 0.0122), gabapentin (p = 0.0006), and
buprenorphine + gabapentin (p < 0.0001) were all significantly lower than the mean body mass
of the vehicle control dams. Significant differences were also observed among the various pup
groupings across treatment [F(3, 42) = 140.4, p < 0.0001], genotype [F(1, 42) =
12.66, p =0.0009], treatment × sex [F(3, 42) = 4.487, p = 0.0081], and genotype × sex [F(1, 42)
= 5.627, p = 0.0223]. No significance was found for the main effect of sex [F(1, 42) =
0.5268, p = 0.4720] or the interactions of treatment × genotype [F(3, 42) = 1.301, p = 0.2866] or
treatment × genotype × sex [F(3, 42) = 2.039, p = 0.1229]. Of note, key differences between
treatments that reached significance included: WT male vehicle vs. either WT male
buprenorphine (Bup) or WT male buprenorphine plus gabapentin (BupGBP), WT female vehicle
vs. WT female BupGBP; Het male vehicle vs. either Het male Bup or Het male BupGBP, and
Het female vehicle vs. Het female BupGBP.
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Body Mass of Mice at P21 Sacrifice Date
Treatment

Wildtype
(WT)
Heterozygous
(α2δ-1 +//Het)
Dams

Sex
Mass
(g)
Sex
Mass
(g)
Mass
(g)

Vehicle Control

30 mg/kg
Gabapentin

5 mg/kg
Buprenorphine

Male Female
(n = 3) (n = 4)
10.00
9.03 ±
± 0.12
0.22
Male Female
(n = 5) (n = 6)
10.15
9.33 ±
± 0.25
0.14
n=4

Male Female
(n = 2) (n = 4)
9.00 ± 9.98 ±
0.35
0.38
Male Female
(n = 3) (n = 4)
10.30
9.53 ±
± 0.55
0.25
n=5

Male Female
(n = 3) (n = 3)
7.20 ± 7.80 ±
0.62
0.31
Male Female
(n = 4) (n = 3)
8.33 ± 8.60 ±
0.11
0.07
n=4

5 mg/kg
Buprenorphine
+ 30 mg/kg
Gabapentin
Male Female
(n = 4) (n = 3)
11.73
12.05
± 0.31 ± 0.09
Male Female
(n = 4) (n = 3)
12.50
12.07
± 0.06 ± 0.13
n=5

33.30 ± 0.35

30.63 ± 0.25

31.35 ± 0.48

27.30 ± 0.36

Table 7: Body Mass of Dams and Pups (Shown as Mean ± SEM) in Each Treatment and
Genotype Group at P21 Perfusion Date

Early Life Exposure to Buprenorphine Increases Excitatory Synapses in the Mesolimbic
Dopamine Pathway
Fluorescence IHC followed by confocal imaging was used to distinguish and quantify
excitatory glutamatergic synapses within three different brain regions of WT mouse pups at P21
(Figure 5) in order to determine whether excitatory synaptic development within the mesolimbic
dopamine pathway was significantly impacted by the presence of buprenorphine and/or
gabapentin in utero. Synapses were identified by the co-localization of presynaptic VGluT1 and
postsynaptic PSD95 (see Figure 4). This type of imaging-based synapse analysis relies on the
fact that these markers are expressed in completely different neuronal compartments (i.e.
VGluT1 in axons, PSD95 in dendrites), and would only appear co-localized in confocal
microscopy when directly opposed at sites of synaptic contact. Beginning with excitatory
glutamatergic synapses within the ACC (Figure 5A), a significant main effect between groups
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(H = 99.00, p < .0001) was observed. Mice treated with either buprenorphine or buprenorphine
in combination with gabapentin had a significantly increased mean number of synapses than
mice treated with vehicle control. Interestingly, gabapentin treatment on its own did not
significantly impact excitatory synapse number compared to vehicle, despite its known role as an
inhibitor of prominent synaptogenic pathways (Eroglu et al., 2009). Similar results were also
observed within the NAC (Figure 5B; H = 119.2, p < .0001), with buprenorphine and
buprenorphine together with gabapentin having significantly more synapses than vehicle, with no
significant effect of gabapentin alone. However, in the NAC, the combination drug treatment
group also exhibited a significantly higher number of synapses than the gabapentin-only group.
In contrast, within the PFC (Figure 5C; H = 165.0, p < .0001), no significant differences were
observed among any of the treatment groups when compared to vehicle.
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Figure 5: Increased Excitatory Synapses with Early Life Buprenorphine Exposure
(A–C) Representative IHC images (left) and quantification (right) of co-localized VGluT1
(green) and PSD95 (red) excitatory synaptic puncta (yellow arrowheads) from early life drugexposed WT C57Bl/6J P21 mouse brain within (B) the anterior cingulate cortex (ACC), (C)
nucleus accumbens (NAC), and (D) prefrontal cortex (PFC). n = 7 (vehicle control), 6 (GBP), 7
(Bup+GBP), 6 (Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Combined Buprenorphine/Gabapentin Exposure Decreases Inhibitory Synapse Number
The same IHC procedure used for glutamatergic excitatory synapses was next used to
stain for GABAergic inhibitory synapses (identified by the co-localization of presynaptic VGAT
and postsynaptic gephyrin; Figure 6) within the same brain regions of the previously analyzed
WT pups. As with excitatory synapses, a main effect of treatment (H = 196.5, p < .0001) was
observed for inhibitory synapses within the ACC (Figure 6A). A significant decrease in mean
number of inhibitory synapses was observed in the combination drug treated mice compared to
all other treatment groups. As with excitatory synapses, similar observations were made in the
NAC (Figure 6B; H = 219.8, p < .0001), with the buprenorphine plus gabapentin group having
significantly fewer inhibitory synapses than the other groups. The PFC, however, was the only
region that exhibited an increase in inhibitory synapse number with any of the drug treatments
(Figure 6C; H = 121.8, p < .0001), with the buprenorphine treatment group having significantly
more VGAT/gephyrin co-localized puncta than the vehicle control group. Yet, as in the ACC and
NAC, the combination treated mice had significantly fewer synapses within the PFC than mice
from either of the single drug treatment groups, but not compared to vehicle control.
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Figure 6: Dual Exposure to Buprenorphine and Gabapentin Decreased Inhibitory
Synapses at P21
(A–C) Representative IHC images (left) and quantification (right) of co-localized VGAT (green)
and gephyrin (red) inhibitory synaptic puncta (yellow arrowheads) from early life drug-exposed
WT C57Bl/6J P21 mouse brain within (A) ACC, (B) NAC, and (C) PFC. n = 7 (vehicle control),
6 (GBP), 7 (Bup+GBP), 6 (Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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α2δ-1 Haploinsufficiency Results in Region- and Treatment-Specific Differences in
Synaptic Connectivity
Gabapentin has previously been shown to inhibit excitatory synapse formation by binding
to the neuronal calcium channel subunit α2δ-1 (Eroglu et al., 2009), and this mechanism is
proposed to underlie the efficacy of gabapentin in the alleviation of symptoms in both epilepsy
and neuropathic pain (Chen H, 2015; Field et al., 2006). Deficits in synaptic connectivity have
previously been observed in the brains of young mice lacking α2δ-1 (Risher et al., 2018). To
determine whether α2δ-1-mediated synaptic development is impacted by early life drug
exposure, synapse analysis was expanded to compare WT synapse numbers with those in mice
that were haploinsufficient for α2δ-1 (Figure 7). Comparing excitatory synaptic development,
within the ACC (Figure 7A; H = 99.00, p < .0001), only the gabapentin treated α2δ-1 +/- mice
showed a significantly greater number of synapses compared with WT mice that received the
same treatment. A similar gabapentin-induced increase was observed within the NAC (Figure
7B; H = 119.2, p < .0001). The same held true for the α2δ-1 +/- PFC (Figure 7C; H = 165.0, p <
.0001), which also exhibited more synapses than WT mice with buprenorphine treatment.

DISCUSSION
Glutamatergic signaling has been shown to be critical to many different aspects of opioid
abuse and addiction (Heinsbroek et al., 2021). Previous studies have shown that morphineinduced activation of dopaminergic neurons cannot occur within the VTA without glutamatergic
associated with heroin addiction and reinstatement of heroin-seeking behavior in rats
(LaLumiere & Kalivas, 2008). In addition, GABAergic synaptic activity has also been heavily
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Figure 7: Altered Excitatory Synaptic Connectivity Following Early Life Drug Treatment
in α2δ-1 Haploinsufficient Mice
Representative IHC images (left) of co-localized VGluT1 (green) and PSD95 (red) excitatory
synaptic puncta (yellow arrowheads) from early life drug-exposed α2δ-1 +/- (Het) C57Bl/6J P21
mouse brain with quantification (right) compared to WT C57Bl/6J P21 mouse brains with the
same early life treatment within (A) ACC, (B) NAC, and (C) PFC. Het: n = 11 (vehicle control),
7 (GBP), 7 (Bup+GBP), 7 (Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Figure 8: α2δ-1-Influenced Changes in Inhibitory Synapse Development in Drug-Exposed
Pups
Representative IHC images (left) of co-localized VGAT (green) and gephyrin (red) inhibitory
synaptic puncta (yellow arrowheads) from early life drug-exposed α2δ-1 Het C57Bl/6J P21
mouse brain and quantification (right) compared to WT C57Bl/6J P21 mouse brains with the
same early life treatment within (A) ACC, (B) NAC, and (C) PFC. Het: n = 11 (vehicle control),
7 (GBP), 7 (Bup+GBP), 7 (Bup); *p < 0.05; **p < 0.01; **p < 0.001; ****p < 0.0001
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implicated in the acute response to drugs and the reinforcement of drug seeking behavior
(Gardner, 2011). However, relatively little is known about how exposure to drugs of abuse
during critical developmental periods affects the trajectories of these synaptic populations. The
goal of this study was to investigate the effects of early life drug exposure on synaptic
development within brain regions associated with addiction and reward, as well as to explore the
role of the gabapentin receptor, α2δ-1, in these alterations of synaptogenesis. Results indicate
that excitatory and inhibitory synaptic populations are significantly disrupted by early life
exposure to buprenorphine and gabapentin, separately or in combination, and that these
disruptions are strongly influenced by α2δ-1 function.
Significant increases in excitatory glutamatergic synapses were observed in multiple
regions associated with the mesolimbic dopamine reward pathway in WT mice that had
undergone early life exposure to only buprenorphine or buprenorphine in combination with
gabapentin. Concomitantly, mice exposed to the combination buprenorphine-gabapentin
treatment in utero showed significant decreases in inhibitory GABAergic synapses compared to
the vehicle control group within these same regions. In addition, the combined impact of
buprenorphine and gabapentin resulted in significantly lower numbers of inhibitory synapses
compared to either single drug treatment in all three brain regions, suggesting a synergistic effect
of polysubstance use on synaptic development. Given the increased prevalence of polysubstance
abuse in mothers of infants born with NAS, as well as the worsened clinical conditions observed
in many of these children (Labella et al., 2021; Egil Nygaard et al., 2018), this finding is of
particular concern.
Taken together, these results indicate a net increase in excitatory glutamatergic signaling
capability within the mesolimbic dopamine pathway of mice exposed to buprenorphine and
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gabapentin. Glutamatergic neurotransmission is heavily implicated in many aspects of drug use,
including acute effects, consolidation, craving/seeking, withdrawal, and relapse (Heinsbroek et
al., 2021). Whether the synaptic population shifts observed in this study result in greater
dopamine release in response to rewarding stimuli, such as drugs of abuse, or a greater risk for
developing substance abuse disorder later in life remains to be elucidated. Studies examining
functionality of dopaminergic neurons and addiction-related behaviors in a similar mouse model
(see Chapter 4) will likely be important parts of future investigations.
Drug Dosing Paradigm Correlates
The dosing for buprenorphine in this study was in line with a study by Martin et al. that
showed 5 mg/kg to be capable of producing significant increases in pain threshold in rats (Martin
et al., 2001). The gabapentin dosage was chosen based on the finding that 30 mg/kg gabapentin
was sufficient to produce analgesia in mice (Kilic et al., 2012). The dosing schedule, starting on
E7 and ending on P11, was chosen to correspond to a period of significant synaptogenesis and
astrocyte development in mice (Farhy-Tselnicker & Allen, 2018). This period also roughly
correlates to the second trimester of human fetal development (Christopherson et al., 2005; De
Felipe et al., 1997; Farhy-Tselnicker & Allen, 2018; Hill, 2020; Otis & Brent, 1954). At birth, a
mouse pup is considered to be at a developmental stage similar to that of a human fetus in the
late second trimester. Despite the fact that newborn mouse pups are no longer receiving direct
exposure to drugs of abuse via the placental blood supply, there were still precedents in the
literature for postnatal drug transference to the brains of pups being nursed by drug-exposed
dams. It has previously been demonstrated that buprenorphine accumulates and remains in the
brain tissue of newborn rodents for several days following birth (Kongstorp et al., 2019). In
addition, both buprenorphine and gabapentin have been shown to pass from mother to infant via
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breast milk, albeit in low concentrations compared to the mothers’ blood plasma levels
(Kristensen et al., 2006; Lindemalm et al., 2009; Ohman et al., 2005). The presence of both
buprenorphine and gabapentin in the brains of drug exposed pups was confirmed, though the
levels in our study were admittedly at the lower ends of the ranges reported in the referenced
works. Regardless, the results of this study show that the chosen treatment paradigm was capable
of disrupting normal CNS synaptic development in mouse pups. The fact that relatively lower
concentrations were detected in these animals may even suggest that the observed deficits may
have been further exacerbated if the accumulated drug levels had been higher.
Gabapentin, α2δ-1, and Astrocytes
Unexpectedly, single drug treatment with gabapentin did not result in any significant
differences in excitatory or inhibitory synapses within any of the examined brain regions in the
WT. This finding would appear to contradict the findings of previous studies showing that
gabapentin inhibits normal excitatory synapse development by interfering with pathways
mediated by α2δ-1. It may be possible that, despite interference by gabapentin in normal
TSP/α2δ-1 mediated synaptic development, the net level of synaptogenesis is maintained via
other signaling mechanisms (Allen et al., 2012; Baldwin & Eroglu, 2017; Kucukdereli et al.,
2011; Walker et al., 2020) as a means to compensate for the gabapentin-induced decrease in
glutamate release. There is evidence that gabapentin may even have a separate mechanism of
action in addition to its binding to α2δ-1 and interference with normal interaction between TSP
and α2δ-1 (Lana et al., 2016). It has also been shown that gabapentin binding to α2δ-1 can
instead interfere with binding between α2δ-1 and NMDA-type glutamate receptors (J. Chen et
al., 2018), inhibiting glutamate signaling in the synapse. A mechanism such as this may
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contribute to the overall changes in excitatory-inhibitory synapse balance seen in gabapentin
treated mice.
In this study, a mouse model of early life drug exposure was used to examine the effects
such exposure may have on synaptic development within brain regions traditionally associated
with reward and addiction. Though there were key regional differences, an overall increase in
glutamatergic excitatory synapses as well as a general decrease in GABAergic inhibitory
synapses was observed in the mesolimbic dopamine pathway of mice exposed to buprenorphine
or buprenorphine in combination with gabapentin. Such changes in synapse number may indicate
a general increase in net excitation in response to rewarding stimuli. α2δ-1, which binds to
gabapentin and is involved in critical synaptogenic pathways mediated by astrocytes, was also
shown to have an important role in the changes in synapse formation induced by early life drug
exposure, as evidenced by the significant differences observed between WT and α2δ-1
haploinsufficient animals. This work may serve to inform future studies examining the effects of
these changes in synapse formation as well as more longitudinal studies that may link history of
early life drug exposure with altered reward circuitry and addiction-like behavior in adolescents
and adults.
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CHAPTER 4
AN INVESTIGATION OF ALTERATIONS IN SYNAPTIC DEVELOPMENT AND
ADDICTION RELEVANT BEHAVIORS IN A BRAIN SPECIFIC Α2Δ-1 KNOCKOUT
MODEL OF EARLY LIFE DRUG EXPOSURE
INTRODUCTION
In the previous chapter, an attempt was made to elucidate the role of α2δ-1 in synaptic
development within a drug exposed brain. The goal of this study was, initially, to compare
littermate pups with three possible α2δ-1 genotypes, α2δ-1 +/+ (WT), α2δ-1 +/- (Het), and α2δ-1
-/- (knockout; KO), and four different possible early life treatments: 5 mg/kg buprenorphine, 30
mg/kg gabapentin, a combination of both drug doses, or a vehicle control. However, after several
attempts to breed α2δ-1 KO pups, it was found that such pups were either not being born or did
not survive to age P21, particularly in the buprenorphine or gabapentin treatment groups. At least
four α2δ-1 KO pups that were present at P7 tattoo date were observed as missing or dead before
or at P21 weaning date. Given the widespread presence of α2δ-1 throughout the mouse CNS
(Cole et al., 2005; Nieto-Rostro et al., 2018), skeletal muscle (Catterall et al., 1988; Tanabe et al.,
1987), and cardiac muscle (Klugbauer et al., 1999), the global knockout of this Ca2+ channel
subunit, in combination with exposure to drugs of abuse during fetal development, may have
been potentially lethal.
Despite the difficulty in generating the necessary number of drug exposed α2δ-1 KO
pups for this study, significant drug treatment effects on synaptic development were still
observed with the loss of just a single copy of α2δ-1, which may indicate that astrocyte-mediated
synaptogenic pathways were disrupted with the drug treatment paradigms. In order to improve
survival rates among α2δ-1 KO pups, a new transgenic conditional α2δ-1Thy1 mouse line on
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mixed C57Bl/6J-FVB/NJ background was generated to repeat the IHC studies performed in the
C57Bl/6J mice (Figure 9). As in the C57Bl/6J mouse IHC study, it was hypothesized that early
life exposure to buprenorphine, gabapentin, or a combination of both drugs would lead to
significant disruptions in excitatory and inhibitory synaptic connectivity in brain regions
associated with addiction and reward and that reduced expression of α2δ-1, either as
haploinsufficiency or as a brain specific knockout, would result in further disruption of these
synaptic populations.
Even if changes in synaptic development do occur as a result of early life drug exposure,
the changes will not be expected to significantly impact the long-term development of the CNS if
they are not permanent and are naturally corrected/repaired early in life. To assess whether the
changes in synaptogenesis persist throughout life, this study included a separate cohort of
postnatal day 70 (P70) mice, an age at which mice have reached full sexual maturity and
adulthood, to compare against the P21 adolescent (pre-sexual maturity) mice.
While IHC studies can show changes in molecular expression and are useful in studying
changes in synaptic development due to early life drug exposure in a mouse model, they can not
demonstrate how these developmental changes might translate into changes in behavior in that
mouse. To date, few studies have investigated whether early life drug exposure might predispose
an individual towards developing a substance use disorder later in life. Although it has been
shown that some forms of addiction carry a level of heritability (Ducci & Goldman, 2012), only
a small number of studies have attempted to isolate prenatal drug exposure as the sole potential
contributing factor to increased risk of developing a substance use disorder. In one such study,
rats prenatally exposed to morphine were shown to demonstrate increased morphine self-
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Figure 9: Confirmation of Forebrain-Specific Conditional α2δ-1 Knockout Mouse
(A) Representative images of Cre expression (green) under the Thy1 promoter. Positive staining
can be seen in P14 brain (cortex and hippocampus shown) but not in liver, kidney, or heart tissue
(DAPI = blue). (B) Western blot against α2δ-1 (143 kDa) in P14 tissue lysates showing loss of
α2δ-1 expression in cortex (lanes 2-7) but not heart (lanes 8-13). n = 3 WT, 3 KO (i.e. α2δ-1Thy1
cKO)

administration (Hovious & Peters, 1985) as well as enhanced conditioned place preference when
treated with morphine as adults (Gagin et al., 1997). In a similar study, rats prenatally exposed to
heroin demonstrated increased self-administration of both heroin and cocaine, a stimulant drug
with a different mechanism of action to that of opioids (Ramsey et al., 1993). Given the
involvement of opioids in the development of the reward pathway and the effects astrocytes can
have on synaptogenesis in these regions, it is possible that prenatal exposure to opioids may
predispose the brain towards addiction to other rewarding stimuli including other drugs of abuse.
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Findings such as these as well as the general lack of longitudinal data examining humans with a
history of prenatal drug exposure are what prompted this study’s inclusion of several different
behavioral assays.
This study attempted to connect changes in synapse number within the mesolimbic
dopamine pathway to changes in behavior through the use of a seven-week behavioral study
regimen. Light/Dark chamber, Open Field, Conditioned Place Preference (CPP), and Vapor
Chamber Self-Administration were chosen for this regimen due to them previously being used in
studies assessing behaviors traditionally associated with anxiety, reward seeking, and impulsivity
(Avelar et al., 2019; Bourin & Hascoët, 2003; Chen H, 2015; Cooper et al., 2020; Henderson &
Cooper, 2021; Leite Junior et al., 2019; Seibenhener & Wooten, 2015). All of these behaviors
can in some way be connected to synaptic signaling within the mesolimbic dopamine pathway. It
was hypothesized that mice exposed to drugs of abuse during prenatal and early life development
would show heightened anxiety. This would manifest as fewer entrances and less time spent in
the light compartment of Light/Dark chamber, less time spent in the center of the Open Field,
and more time spent in thigmotaxis around the edges of the Open Field. It was also hypothesized
that early life drug exposure would increase preference for the chamber associated with nicotine
injections in CPP experiments and would cause mice to initiate a greater number of nose pokes
in order to self-administer vaporized nicotine compared to drug-naïve animals. In addition, it was
expected that reduced expression of α2δ-1 within the brain would dysregulate these behavioral
phenotypes.
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MATERIALS AND METHODS
Animals and Drug Treatments
Experiments were conducted in accordance with Marshall University’s Institutional
Animal Care and Use Committee (IACUC) guidelines (W.C.R. protocols 696 and 697). Adult
C57Bl/6J mice heterozygous for Cacna2d1 were a kind gift from Dr. Cagla Eroglu (Duke
University). These mice were crossed with the FVB/N-Tg(Thy1-cre)1Vln/J line (The Jackson
Laboratory, Bar Harbor, Maine), which express Cre recombinase under the control of the
forebrain neuron-specific Thy1 promoter. The mice were bred onsite at the Marshall University
Animal Resource Facility. Confirmation of the resulting brain-specific knockout of α2δ-1 in
these mice was obtained via IHC and Western blotting (Figure 9). Methods used in setting
mouse mating pairs and caring for the animals were identical to those used in the C57Bl/6J
mouse studies. The same four treatments (5mg/kg buprenorphine, 30mg/kg gabapentin, 5mg/kg
buprenorphine + 30mg/kg gabapentin, and vehicle control) and the treatment schedule were also
used.
Before any experiments were performed or statistical analyses were conducted, a power
analysis was conducted using the software G*Power (Version 3.1.9.6, Franz Faul Universität
Kiel, Germany) to determine appropriate sample sizes for each age-genotype-treatment group
that would still possess power (1 – β) equal to or greater than 0.8. Effect size was set at four and
the α error probability was set at 0.05. It was determined that approximately four mice per group
would be sufficient to reliably produce results reaching level of statistical significance in the
planned IHC studies. For the P21 mouse group treated with the vehicle control, five litters were
produced from which five wild-type (WT) mice (three male, two female), five α2δ-1 +/flox
conditional heterozygous (cHet) mice (three male, two female), and five α2δ-1 flox/flox
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conditional knockout (cKO) mice (two male, three female) were included. Five litters were
treated with gabapentin in order to produce 5 WT mice (two male, three female), five cHet mice
(three male, two female), and five cKO mice (three male, two female). Four litters were treated
with the combination of buprenorphine and gabapentin in order to produce six WT mice (two
male, four female), six cHet mice (three male, three female), and five cKO mice (three male, two
female). Five litters were treated with buprenorphine in order to produce four WT mice (two
male, two female), five cHet mice (two male, three female), and five cKO mice (three male, two
female) (Table 8).
For the P70 mouse group, the number of mice per group was increased to more closely
align with methods described in previous literature. Two litters were treated with the vehicle
control from which six WT mice (three male, three female) and seven cHet mice (three male,
four female) were included in studies. Four litters were treated with gabapentin in order to
produce eight WT mice (four male, four female) and six cHet mice (three male, three female).
Three litters were treated with the combination of buprenorphine and gabapentin in order to
produce seven WT mice (two male, five female) and seven cHet mice (three male, four female).
three litters were treated with buprenorphine in order to produce eight WT mice (four male, four
female) and seven cHet mice (three male, four female) (Table 9). Dams were not weighed and
were instead euthanized following weaning at P21.
Genotyping
At P7, the tails of the pups were clipped and collected. Toe pads were tattooed (AIMS
NEO9 Animal Tattoo System, Hornell, NY) for later identification. Tissue digestion was
performed on the clipped tails and DNA was isolated for PCR amplification and genotyping with
a 2% agarose gel. C57Bl/6J-FVB/NJ α2δ-1Thy1 pups were first identified as either Cre positive or
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negative using the following primers: Cre sense (5’-GAACCTGATGGACATGTTCAGG-3’),
Cre anti-sense (5’-AGTGCGTTCGAACGCTAGAGCCTGT-3’), myogenin sense (5’TTACGTCCATCGTGGACAGC-3’), and myogenin anti-sense
(5’TGGGCTGGGTGTTAGCCTTA-3’) (Integrated DNA Technologies, Coralville, IA). All
pups identified as Cre positive were then further identified as one of three genotypes: α2δ-1 +/+
wild-type (WT), α2δ-1 +/flox heterozygous (cHet), or α2δ-1 flox/flox knockout (cKO). The
primers that were used in the genotyping of C57Bl/6J pups were used again: F1 (WT forward,
5’-TCTCAGTTACAAGACTATGTGG-3’), F3 (KO forward, 5’GGCTGTGTCCTTATTTATGG-3’), and LAF-Test (reverse, 5’AGTAGGAGAAGGTACAATCGGC-3’) (Integrated DNA Technologies).
Immunohistochemistry Studies
For the P21 mouse group, when a litter reached P21, the dam and pups were placed
individually on a scale to be weighed (group data is included in Table 8) The same techniques
for brain perfusion, freezing, sectioning, and immunostaining that were used for C57Bl/6J mice
were used again for this study (Figures 1 and 4). For each litter in the P70 mouse group, pups
were weaned at P21, placed in new cages (two to five mice per cage and separated by sex), and
the dam was euthanized via carbon dioxide inhalation. At P70, the mice were weighed,
anesthetized, and perfused and their brains were frozen and cryosectioned as described above
(Table 9). The same procedures for immunohistochemistry, confocal microscopy, and image
analysis were also used.

66

Behavioral Studies
Handling
Procedures for the behavioral experiments chosen for this study are based on those
previously used in studies of addiction and drug exposure (Avelar et al., 2019; Bourin &
Hascoët, 2003; Buccafusco, 2009; Chen H, 2015; Henderson & Cooper, 2021; Leite Junior et al.,
2019; Seibenhener & Wooten, 2015). Behavioral studies followed a seven-week schedule (as
shown in Figure 10). At least 24 hours following weaning, mice designated to participate in
behavioral studies were handled in the room in which behavioral trials were set to take place.
Every morning for five days, each mouse was held in gloved hands for 10 minutes in order for
the mice to acclimatize to the handler and the lab environment. The time of day and the order in
which mice were handled was maintained for all five days. Gloves were cleaned and disinfected
in between mice. Mice were allowed to habituate for at least 30 minutes after being transported
to the testing room prior to behavioral testing.
Light/Dark Testing
Three days after their last handling session (at approximately P30), mice underwent
light/dark testing. Mice were placed in the Light zone chamber (ambient light 60 lux) of a
Light/Dark chamber and allowed to move freely between Light and Dark zone (ambient light <
10 lux) chambers (both 8”x16” in area) via a single, small opening (Bourin & Hascoët, 2003).
Mice were video recorded for 10 minutes. Videos were analyzed with ANY-maze software
(Wood Dale, IL) to track the number of entries to the Light zone and total time spent in the Light
zone. Both chambers were cleaned and disinfected in between trials. Mice were allowed to
habituate for at least 30 minutes after being transported to the testing room prior to behavioral
testing.
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Open Field
Four days following light/dark testing (at approximately P34), mice underwent Open
Field testing. Mice were placed in the center of a 37 cm × 37 cm Open Field chamber where
ambient light was adjusted to 60 lux. Mice were allowed to move freely in the chamber while
being video recorded for 10 minutes. Videos were analyzed with ANYmaze to track total time
spent in the center zone of the field, total entries to the center zone, total time spent in
thigmotaxis near the walls at the edge of the field, and total distance traveled. The chamber was
cleaned and disinfected in between trials. Mice were allowed to habituate for at least 30 minutes
after being transported to the testing room prior to behavioral testing.
Conditioned Place Preference (CPP)
Three days after Open Field testing (at approximately P37), mice began conditioned
place preference (CPP) testing. CPP assays were performed with a three-chamber spatial placepreference chamber (Harvard Apparatus, PanLab Item #76-0278, dimensions: 47.5 × 27.5 × 47.5
cm) and largely followed previously published methods (Avelar et al., 2019; Avelar et al., 2022;
Lee et al., 2020). An unbiased 10-day protocol was used with a Pretest session held on Day One.
Mice were placed in the neutral adjoining chamber connecting the two separate larger chambers,
each with a distinct wall pattern and floor texture, and allowed to travel freely between the two
chambers as they were video recorded for 10 minutes. On Days Two, Four, Six, and Eight, mice
received a 0.5 mg/kg intraperitoneal injection of nicotine ditartrate dihydrate 98% (Thermo
Fisher Scientific Waltham, MA) dissolved in normal saline before being placed in the drugpaired chamber for 20 minutes. On Days Three, Five, Seven, and Nine, mice received an
injection of saline (equal in volume to the previous day’s nicotine injection) before being placed
in the saline-paired chamber for 20 minutes. On Day Ten, the Post-test session was held with
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mice will again being placed in the neutral adjoining chamber and allowed to travel freely
between the drug-paired and saline-paired chambers while being video recorded for 10 minutes.
The time of day and the order in which mice were placed in chambers were consistent for all 10
days. All chambers were cleaned and disinfected in between trials. Mice were allowed to
habituate for at least 30 minutes after being transported to the testing room prior to behavioral
testing. Videos of the Pre- and Post-tests were analyzed with ANYmaze to record the amount of
time spent in each chamber during the two testing phases and CPP scores were calculated using
the following formula:
CPP score = (A – B)post-test – (A – B)pretest
A = Drug-paired
B = Saline-paired

Self-Administration
Two days following the CPP Post-test session (at approximately P50), mice began the
acclimation phase of vapor self-administration testing. Testing followed slight modifications of
the established protocol and utilized the self-administration chambers described in previous work
by Dr. Skylar Cooper and Dr. Brandon Henderson (Cooper et al., 2020; Henderson & Cooper,
2021). On Days One, Three, and Five, mice were placed in an acclimating vapor chamber for
one hour. A three second puff of vaporized solution containing 3mg/ml nicotine-salt dissolved in
1:1 propylene glycol: vegetable glycerin (PGVG) was released once every five minutes. On Day
Six, mice began operant training. Mice were placed in an operant chamber containing an active
and inactive nose poke. Each active nose-poke delivered a three second vapor puff on a fixed
ratio 1 (FR1) schedule and was immediately followed by the illumination of a cue-light inside
the nose-poke hole that remained illuminated for a 60 second timeout. Inactive nose-pokes,
which elicited no response, were also recorded. Mice participated in daily one-hour FR1 sessions
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for 10 days. At the end of these 10 days, mice were assessed for reinforcement. If a mouse
showed consistently high numbers of nose pokes, if the number increased gradually over time, or
if the number increased suddenly after being relatively low for several days, these were taken as
potential signs of reinforcement. Mice that demonstrated reinforcement were transitioned to a
daily one-hour fixed ratio 3 (FR3) schedule (three active nose-pokes required for a three second
vapor puff to be delivered followed by a 60-second timeout) for three days starting on the day
immediately following the final FR1 session. The mean number of active nose-pokes from the
final two FR3 sessions was calculated (Henderson & Cooper, 2021). The time of day and the
order in which mice were placed in chambers was consistent and all chambers were cleaned and
disinfected in between sessions. Mice were allowed to habituate for at least 30 minutes after
being transported to the testing room prior to behavioral testing.

Figure 10: Schedule for Behavioral Studies for Each Mouse in the P70 Group, Beginning at
P22 and Ending at P70

Statistical Analysis
For body mass comparisons, dams belonging to different treatment groups were
compared via One-Way ANOVA with Tukey’s multiple comparisons post hoc test. For pups, a
Three-Way ANOVA (treatment × genotype × sex) was performed with Tukey’s multiple
comparisons post hoc test. For IHC studies, the D’Agostino and Pearson omnibus normality test
confirmed that most synapse counts were not normally distributed. Therefore, statistical
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differences between synapse counts were analyzed using the nonparametric Kruskal-Wallis test
to detect differences in mean number of synapses amongst drug treatments or between
genotypes. Post-hoc Dunn’s multiple comparisons tests were performed to detect significant
differences (p < 0.05) amongst the mean values of each treatment group.
Multiple statistical methods were required for behavioral studies. D’Agostino and
Pearson omnibus normality tests were performed for each data set to determine whether or not
nonparametric statistical testing was necessary. For light/dark testing, the nonparametric
Kruskal-Wallis test and post-hoc Dunn’s multiple comparisons tests were performed. For
analysis of the Open Field studies examining center zone entries, time spent in the center zone,
and time spent freezing, Kruskal-Wallis test and post-hoc Dunn’s multiple comparisons tests
were performed. For analyses of time spent in thigmotaxis and total distance traveled within the
Open Field, however, Two-way ANOVA (treatment × genotype) with Tukey’s multiple
comparisons post hoc tests were used. In the CPP analyses, the CPP scores among WT mice
were analyzed using One-way ANOVA with Tukey’s multiple comparisons post hoc test,
whereas the comparisons between WT and Het mice were analyzed with Two-way ANOVA
(treatment × genotype) and Tukey’s multiple comparisons post hoc test. The mean number of
nose pokes for each treatment-genotype mouse group for each of the 10 days of FR1 selfadministration testing were analyzed with Kruskal-Wallis test and post-hoc Dunn’s multiple
comparisons test. The mean averages of the last two days of FR3 for each treatment-genotype
group of mice that demonstrated reinforcement during FR1 were analyzed with Kruskal-Wallis
test and post-hoc Dunn’s multiple comparisons test. All analyses were performed using
GraphPad Prism and all graphs, where applicable, were shown with bars representing Standard
Error of the Mean (SEM).
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RESULTS
Body Mass of Pups Impacted by Drug Treatment and Expression of α2δ-1
The mean masses for the dams of the different litters and the pups in each age-sexgenotype-treatment group were calculated and compared (Tables 8 and 9). Among the P21
group, significant main effect was observed in treatment × genotype [F(11, 80) = 4.070, p <
0.0001]. One notable finding was that among pups with the cKO genotype, those treated with
gabapentin (p = 0.014) and those treated with buprenorphine (p < 0.0001) had significantly lower
average body masses compared to the cKO vehicle control. No other interactions among the
pups rose to the level of significance, nor were any significant differences observed among the
dams.
In the P70 group, a significant main effect was again observed in treatment × genotype
[F(7, 45) = 3.842, p = 0.0024]. WT mice treated with gabapentin (p = 0.0036) and WT mice
treated with buprenorphine (p = 0.0125) had average body masses significantly greater than
vehicle treated WT mice. A significant main effect was also observed in treatment × genotype ×
sex [F(15, 41) = 10.18, p < 0.0001]. Gabapentin treated WT females had a significantly greater
average body mass than vehicle treated WT females (p = 0.0028), vehicle treated Het males were
significantly greater than vehicle treated Het females (p = 0.0015), and buprenorphine treated
WT males were significantly greater than buprenorphine treated WT females (p < 0.0001).
In addition to these body mass measurements, there were a number of observational findings not
reflected in the data. The plastic dishes in which those treatments were served were, as in the
C57Bl/6J mice, consistently observed to be empty on the day following administration,
confirming that the dams routinely consumed the entirety of the treatment solution. One finding
of note was that 4 pups from gabapentin treated litters and 1 pup from a buprenorphine +
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gabapentin treated litter were either observed to be dead or were missing between the P7 tattoo
date and P21 wean date. It was believed that this group of pups was a combination of both males
and females and genotyping later confirmed that they were all cKO. It was also observed that
pups from gabapentin treated litters appeared hyperactive on their P21 wean dates. They would
attempt to jump out of their cages and often bit experimenters who attempted to pick them up.
While these observations can not be quantified, they may point to a unique and, potentially,
harmful interaction with gabapentin in the developing CNS.
P21 Immunohistochemistry
Early Life Exposure to Gabapentin Decreased Excitatory Synapses in the Mesolimbic
Dopamine Pathway
Fluorescence IHC followed by confocal imaging was used, as it was in the C57Bl/6J
mouse study, to distinguish and quantify excitatory glutamatergic synapses, identified by colocalization of presynaptic VGluT1 and post-synaptic PSD95 (see Figure 1), within the ACC,
NAC, and PFC of α2δ-1Thy1 WT mouse pups at P21 (Figure 11) in order to determine whether
excitatory synaptic development within the mesolimbic dopamine pathway was significantly
impacted by any of the three drug treatments. First examining the ACC, a significant main effect
between groups (H = 338.8, p < 0.0001) was observed. Mice treated with gabapentin showed a
significantly lower number of synapses compared to the vehicle control treated mice (Figure
11A). A similar trend was observed within the NAC (Figure 11B; H = 162.1, p < 0.0001) except
that the gabapentin treatment group showed a significantly lower number of synapses compared
to the vehicle and the combination drug (buprenorphine + gabapentin) treatment groups. The
buprenorphine treated group was also significantly lower than the vehicle. This trend appeared to
reverse within the PFC (Figure 11C; H = 231.7, p < 0.0001) with the buprenorphine and
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Treatment
M/F Ratio
Genotype
Sex
n
Mean Body Mass (g)
Standard Deviation
Combined Mean
Body Mass (g)
Standard Deviation
Treatment
M/F Ratio
Genotype
Sex
n
Mean Body Mass (g)
Standard Deviation
Combined Mean
Body Mass (g)
Standard Deviation
Treatment
M/F Ratio
Genotype
Sex
n
Mean Body Mass (g)
Standard Deviation
Combined Mean
Body Mass (g)
Standard Deviation
Treatment
M/F Ratio
Genotype
Sex
n
Mean Body Mass (g)
Standard Deviation
Combined Mean
Body Mass (g)
Standard Deviation

Body Mass of Mice at P21 Sacrifice Date
Vehicle Control
0.76
WT
cHet
Dams
M
F
M
F
5
3
2
3
2
31.04
12.55
12.70
12.81
12.11
2.59
1.18
0.96
1.37
0.87

Dams
5
31.56
3.96

13.33
12.88
1.00
1.16
30 mg/kg Gabapentin
1
WT
cHet
M
F
M
F
2
3
3
2
10.40
11.44
12.50
11.78
2.69
1.08
1.51
1.40

cKO
M

F

2
15.30
2.55

3
14.56
2.50

13.63
2.32

cKO
M

F

3
11.28
1.73

2
11.38
0.56

11.28
11.95
12.13
1.41
1.45
1.27
5 mg/kg Buprenorphine + 30 mg/kg Gabapentin
1.18
WT
cHet
cKO
Dams
M
F
M
F
M
F
4
2
4
3
3
3
2
31.05
11.78
11.97
13.02
11.83
11.30
10.35
2.66
0.93
1.34
1.13
1.21
3.29
0.07

Dams
5
31.06
4.36

12.33
12.18
1.02
1.24
5 mg/kg Buprenorphine
0.67
WT
cHet
M
F
M
F
2
2
2
3
9.45
10.30
10.75
11.69
0.64
1.84
1.34
2.66
9.88
1.23

9.18
2.47

10.00
2.59

cKO
M

F

3
10.22
2.31

2
7.20
0.99

7.80
2.43

Table 8: Body Mass of α2δ-1Thy1 Dams and P21 Pups in Each Treatment and Genotype
Group at Perfusion Date
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Body Mass of Mice at P70 Sacrifice Date
Treatment
Vehicle Control
M/F Ratio
0.86
Genotype
WT
cHet
Sex
M
F
M
F
n
3
3
3
4
Mean Body Mass (g)
23.13
18.17
25.07
19.78
Standard Deviation
1.71
0.81
0.67
2.45
Combined Mean Body Mass (g)
20.65
22.04
Standard Deviation
2.97
3.34
Treatment
30 mg/kg Gabapentin
M/F Ratio
1
Genotype
WT
cHet
Sex
M
F
M
F
n
4
4
3
3
Mean Body Mass (g)
25.53
23.44
24.80
23.53
Standard Deviation
2.00
1.91
0.87
0.70
Combined Mean Body Mass (g)
24.37
24.17
Standard Deviation
2.13
0.99
Treatment
5 mg/kg Buprenorphine + 30 mg/kg Gabapentin
M/F Ratio
0.5
Genotype
WT
cHet
Sex
M
F
M
F
n
2
5
3
4
Mean Body Mass (g)
24.25
21.15
24.50
20.86
Standard Deviation
1.63
1.48
2.76
1.39
Combined Mean Body Mass (g)
21.93
22.23
Standard Deviation
2.00
2.62
Treatment
5 mg/kg Buprenorphine
M/F Ratio
0.93
Genotype
WT
cHet
Sex
M
F
M
F
n
4
4
3
4
Mean Body Mass (g)
26.46
20.82
25.67
22.06
Standard Deviation
1.59
1.03
1.44
0.61
Combined Mean Body Mass (g)
23.64
23.41
Standard Deviation
3.23
2.07

Table 9: Body Mass of P70 α2δ-1Thy1 Mice in Each Treatment and Genotype Group at
Perfusion Date
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combination treatments being significantly greater than the vehicle control and the gabapentin.
Decreased Expression of α2δ-1 Significantly Decreased the Number of Excitatory Synapses
By comparing synapse numbers between three different genotypes for α2δ-1, the role of
this channel subunit in drug influenced synaptogenesis can be elucidated. Within the ACC
(Figure 12), in α2δ-1Thy1 mice within the vehicle control, gabapentin, and buprenorphine +
gabapentin treatment groups, decreased forebrain expression of α2δ-1 corresponded with a
decrease in glutamatergic excitatory synapses. This trend was not observed in buprenorphine
treated mice, however. A decrease in synapse number corresponding with decreased expression
of α2δ-1 was again seen among the vehicle and the buprenorphine + gabapentin treatment groups
within the NAC (Figure 13). Intriguingly, though, cKO mice treated with gabapentin actually
showed an increase in synapse number compared to WT or Het mice administered the same
treatment. This unique finding appeared to be isolated to the NAC, however, as within the PFC
(Figure 14), mice treated with the vehicle control and the buprenorphine + gabapentin
combination showed a decrease in glutamatergic excitatory synapses, corresponding with
decreased expression of α2δ-1. Buprenorphine treated mice also followed this trend.

76

Figure 11: Formation of Excitatory Synapses Decreased with Early Life Gabapentin
Exposure
(A–C) Representative IHC images (left) and quantification (right) of co-localized VGluT1
(green) and PSD95 (red) excitatory synaptic puncta (yellow arrowheads) from the brains of early
life drug-exposed α2δ-1Thy1 WT mice at P21 within (A) the anterior cingulate cortex (ACC), (B)
nucleus accumbens (NAC), and (C) prefrontal cortex (PFC). n = 5 (vehicle control), 5 (GBP), 6
(Bup+GBP), 4 (Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Figure 12: Presence of α2δ-1 Significantly Impacted Excitatory Synapse Number Within
the Anterior Cingulate Cortex
(A–C) Representative IHC images (forebrain specific α2δ-1 heterozygous left and knockout
right) and quantification of co-localized VGluT1 (green) and PSD95 (red) excitatory synaptic
puncta (yellow arrowheads) from the brains of early life drug-exposed α2δ-1Thy1 mice at P21
within the ACC. n = 5 (cHet Veh), 5 (cHet GBP), 6 (cHet Bup+GBP), 5 (cHet Bup), 5 (cKO
Veh), 5 (cKO GBP), 5 (cKO Bup+GBP), 5 (cKO Bup). *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001
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Figure 13: Response to the Combination of Buprenorphine and Gabapentin Determined by
Presence of α2δ-1 Within the Nucleus Accumbens
(A–C) Representative IHC images (forebrain specific α2δ-1 heterozygous left and knockout
right) and quantification of co-localized VGluT1 (green) and PSD95 (red) excitatory synaptic
puncta (yellow arrowheads) from the brains of early life drug-exposed α2δ-1Thy1 mice at P21
within the NAC. n = 5 (cHet Veh), 5 (cHet GBP), 6 (cHet Bup+GBP), 5 (cHet Bup), 5 (cKO
Veh), 5 (cKO GBP), 5 (cKO Bup+GBP), 5 (cKO Bup). *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001
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Figure 14: Response to Buprenorphine Impacted by the Presence of α2δ-1 in Prefrontal
Cortex
(A–C) Representative IHC images (α2δ-1 cHet left and cKO right) and quantification of colocalized VGluT1 (green) and PSD95 (red) excitatory synaptic puncta (yellow arrowheads) from
the brains of early life drug-exposed α2δ-1Thy1 mice at P21 within the PFC. n = 5 (cHet Veh), 5
(cHet GBP), 6 (cHet Bup+GBP), 5 (cHet Bup), 5 (cKO Veh), 5 (cKO GBP), 5 (cKO Bup+GBP),
5 (cKO Bup). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
Inhibitory GABAergic Synapses Were Significantly Impacted by Early Life Exposure to
Buprenorphine, as a Single Treatment and in Combination with Gabapentin
Fluorescence IHC of presynaptic VGAT and post-synaptic Gephyrin was again used to
distinguish and quantify inhibitory GABAergic synapses (Figure 1) within the ACC, NAC, and
PFC of P21 α2δ-1Thy1 WT pups (Figure 15). No significant differences were observed between
treatment groups within the ACC (Figure 15A; H = 188.5, p < 0.0001). Within the NAC,
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however, the combination buprenorphine + gabapentin treatment group had a significantly
greater number of inhibitory synapses compared to the vehicle control group as well as the
gabapentin solo treatment group (Figure 15B; H = 111.3, p < 0.0001). Within the PFC (Figure
15C; H = 183.2, p < 0.0001), the only significant difference in synapse number was a decrease in
the buprenorphine treatment group compared to the vehicle control group.
Decreased Expression of α2δ-1 Significantly Decreased the Number of Inhibitory Synapses,
But Not in Mice Treated with Gabapentin
Differences in the number of inhibitory synapses were also observed between the three
different genotypes for α2δ-1 (Figure 16). Within the ACC, similarly to what was observed in
excitatory synapses, there was a decrease in synapse number corresponding with decreased
expression of α2δ-1 in the vehicle control, buprenorphine, and buprenorphine + gabapentin
treatment groups. This trend was also observed within the NAC (Figure 17). No significant
differences were observed between the three genotype groups of mice treated with gabapentin in
either the ACC or NAC. However, within the PFC (Figure 18), similarly to what was seen with
excitatory synapses within the NAC, cKO mice treated with gabapentin had a greater number of
inhibitory synapses than either the WT or cHet mice that received the same treatment (although
this difference only rose to the level of significance in the comparison between cKO and cHet).
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Figure 15: Development of Inhibitory Synapses Impacted by Buprenorphine
(A–C) Representative IHC images (left) and quantification (right) of co-localized VGAT (green)
and Gephyrin (red) excitatory synaptic puncta (yellow arrowheads) from the brains of early life
drug-exposed α2δ-1Thy1 WT mice at P21 within (A) the ACC, (B) NAC, and (C) PFC. n = 5
(Veh), 5 (GBP), 6 (Bup+GBP), 4 (Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Figure 16: Presence of α2δ-1 Significantly Impacted Inhibitory Synapse Number Within
the Anterior Cingulate Cortex
(A–C) Representative IHC images (α2δ-1 cHet left and cKO right) and quantification of colocalized VGAT (green) and Gephyrin (red) excitatory synaptic puncta (yellow arrowheads)
from the brains of early life drug-exposed α2δ-1Thy1 mice at P21 within the ACC. n = 5 (cHet
Veh), 5 (cHet GBP), 6 (cHet Bup+GBP), 5 (cHet Bup), 5 (cKO Veh), 5 (cKO GBP), 5 (cKO
Bup+GBP), 5 (cKO Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Figure 17: Buprenorphine Can Affect Changes in Inhibitory Synapse Number Within the
Nucleus Accumbens
(A–C) Representative IHC images (α2δ-1 cHet left and cKO right) and quantification of colocalized VGAT (green) and Gephyrin (red) excitatory synaptic puncta (yellow arrowheads)
from the brains of early life drug-exposed α2δ-1Thy1 mice at P21 within the NAC. n = 5 (cHet
Veh), 5 (cHet GBP), 6 (cHet Bup+GBP), 5 (cHet Bup), 5 (cKO Veh), 5 (cKO GBP), 5 (cKO
Bup+GBP), 5 (cKO Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Figure 18: Gabapentin Capable of Interfering with α2δ-1 Related Decrease in Inhibitory
Synapse Number Within the Prefrontal Cortex
(A–C) Representative IHC images (α2δ-1 cHet and cKO right) and quantification of co-localized
VGAT (green) and Gephyrin (red) excitatory synaptic puncta (yellow arrowheads) from the
brains of early life drug-exposed α2δ-1Thy1 mice at P21 within the PFC. n = 5 (cHet Veh), 5
(cHet GBP), 6 (cHet Bup+GBP), 5 (cHet Bup), 5 (cKO Veh), 5 (cKO GBP), 5 (cKO Bup+GBP),
5 (cKO Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
P70 Immunohistochemistry
Changes in Excitatory Synapses Resulting from Early Life Drug Exposure Persisted into
Adulthood
To determine whether the types of changes in synapse formation observed in mice at P21
persist throughout life, a separate cohort of α2δ-1Thy1 mice were sacrificed and perfused at P70
for the same IHC methods as were used in the P21 group. Within the ACC (Figure 19A),
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staining for VGluT1 and PSD95 to examine excitatory glutamatergic synapses showed a
significant decrease in synapse number in mice exposed to gabapentin and a significant increase
in mice treated with both gabapentin and buprenorphine compared to vehicle control treated
mice (H = 81.53, p < 0.0001). This combination treatment group also had a significantly higher
number of synapses than the buprenorphine single drug group. The buprenorphine treatment
group had a significantly lower number of synapses compared to each of the other treatment
groups within the NAC (H = 97.86, p < 0.0001; Figure 19B). Within the PFC (Figure 19C) both
the gabapentin and the buprenorphine + gabapentin treatment groups showed significantly
greater numbers of synapses than either the vehicle control or buprenorphine groups, yet the
buprenorphine group was significantly lower than the vehicle control (H = 139.7, p < 0.0001).
Persistent Effects of Early Life Drug Exposure on Excitatory Synapses Influenced by
Expression of α2δ-1
The responses to different early life treatments in α2δ-1Thy1 WT P70 mice were
compared to those of α2δ-1Thy1 cHet mice with the goal of determining whether significant
differences in excitatory synapses related to genotype persisted into adulthood. Loss of a single
copy of α2δ-1 did not appear to play as significant a role in excitatory synapse formation as it
had in P21 mice. Within the ACC (Figure 20A), no significant differences were observed
between the two genotypes. Within the NAC (Figure 20B) and PFC (Figure 20C), the only
significant differences observed were in the buprenorphine treatment groups with cHet mice
showing significantly greater numbers of excitatory synapses compared to WT mice in their
respective brain regions.
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Figure 19: Drug Induced Changes in Excitatory Synapse Number Persist into Adulthood
(A–C) Representative IHC images (left) and quantification (right) of co-localized VGluT1
(green) and PSD95 (red) excitatory synaptic puncta (yellow arrowheads) from the brains of early
life drug-exposed α2δ-1Thy1 WT mice at P70 within (A) ACC, (B) NAC, and (C) PFC. n = 6
(Veh), 8 (GBP), 7 (Bup+GBP), 8 (Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
87

Figure 20: Persistent Effects of Early Life Buprenorphine Exposure Influenced by
Haploinsufficiency of α2δ-1
(A–C) Representative IHC images (left) and quantification (right) of co-localized VGluT1
(green) and PSD95 (red) excitatory synaptic puncta (yellow arrowheads) from the brains of α2δ1Thy1 cHet mice at P70 compared with WT mice of the same age within the (A) ACC, (B) NAC,
and (C) PFC. n = 6 (Veh), 7 (cHet Veh), 8 (GBP), 6 (cHet GBP), 7 (Bup+GBP), 7 (cHet
Bup+GBP), 8 (Bup), 7 (cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Inhibitory Synapses Were Significantly Impacted by Early Life Exposure to Both
Buprenorphine and Gabapentin
As in the P21 mouse group, IHC staining for VGAT and Gephyrin was performed in P70
mice to determine the number of inhibitory GABAergic synapses within the three brain regions
of interest. Early life buprenorphine treatment, whether by itself or in combination with
gabapentin, was associated with a significantly lower number of synapses within the ACC
(Figure 21A; H = 209.9, p < 0.0001). Within the NAC, gabapentin treated mice had a
significantly greater number of inhibitory synapses than any other treatment (Figure 21B; H =
303.8, p < 0.0001). In addition, the buprenorphine + gabapentin combination treatment group
had a significantly lower number of synapses compared to either the vehicle control or the
gabapentin single treatment groups. Gabapentin treatment was also associated with a
significantly greater number of synapses compared to any other treatment group within the PFC
(Figure 21C; H = 234.2, p < 0.0001).
Influence of α2δ-1 Expression on Inhibitory Synapses not Observed in Mice with Early Life
Drug Exposure
α2δ-1Thy1 WT P70 mice were also compared to α2δ-1Thy1 cHet mice determining whether
significant differences in inhibitory synapses related to genotype persisted into adulthood. It was
apparent that cHet mice, in all three brain regions, had significantly lower numbers of
GABAergic synapses, as evidenced in the vehicle control groups (Figure 22). However, while
there was a significant difference in synapse numbers within the ACC of WT vs cHet mice
treated with gabapentin (Figure 22A), no significant differences were observed within the NAC
(Figure 22B) or PFC (Figure 22C) in any drug treatment comparisons of these two mouse
groups.
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Figure 21: Early Life Drug Exposure Produces Persistent Changes in Inhibitory Synapse
Number
(A–C) Representative IHC images (left) and quantification (right) of co-localized VGAT (green)
and Gephyrin (red) excitatory synaptic puncta (yellow arrowheads) from the brains of early life
drug-exposed α2δ-1Thy1 WT mice at P70 within (A) the ACC, (B) NAC, and (C) PFC. n = 6
(Veh), 8 (GBP), 7 (Bup+GBP), 8 (Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Figure 22: Effects of Early Life Drug Exposure on Inhibitory Synapse Number is Less
Impacted by Haploinsufficiency of α2δ-1 Over Time
(A–C) Representative IHC images (left) and quantification (right) of co-localized VGAT (green)
and Gephyrin (red) excitatory synaptic puncta (yellow arrowheads) from the brains of α2δ-1Thy1
cHet mice at P70 compared with WT mice of the same age within the (A) ACC, (B) NAC, and
(C) PFC n = 6 (Veh), 7 (cHet Veh), 8 (GBP), 6 (cHet GBP), 7 (Bup+GBP), 7 (cHet Bup+GBP),
8 (Bup), 7 (cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Excitatory Synapses Generally Decrease with Age
Although differences in the numbers of synapses were observed in early life drug
exposed mice at both P21 and at P70, how these differences may have changed over time was
not yet clear. To this end, synapse numbers in each brain region in mice from each age group
were compared within each treatment-genotype. IHC staining for glutamatergic excitatory
synapses within the ACC (Figure 23; H = 515.8, p < 0.0001) showed a general decrease in
synapse number with age in most treatment-genotype groups (excluding gabapentin and
buprenorphine + gabapentin in cHet mice). A similar trend was observed within the NAC
(Figure 24; H = 311.7, p < 0.0001), though not in the gabapentin treated groups in either
genotype nor the buprenorphine + gabapentin in cHet mice. Results very similar to those
observed within the NAC were seen within the PFC (Figure 25; H = 559.0, p < 0.0001) as well.
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Figure 23: Increase in Age Generally Associated with Decrease in Excitatory Synapse
Number Within the Anterior Cingulate Cortex
Comparison of excitatory synapse number between ages with the same genotype and early life
treatment within the ACC. n = 5 (P21 Veh), 5 (P21 cHet Veh), 5 (P21 GBP), 5 (P21 cHet GBP),
6 (P21 Bup+GBP), 6 (P21 cHet Bup+GBP), 4 (P21 Bup), 5 (P21 cHet Bup), 6 (P70 Veh), 7 (P70
cHet Veh), 8 (P70 GBP), 6 (P70 cHet GBP), 7 (P70 Bup+GBP), 7 (P70 cHet Bup+GBP), 8 (P70
Bup), 7 (P70 cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Figure 24: Age Related Decrease in Excitatory Synapse Number Not Equal Across Drug
Treatment Groups Within the Nucleus Accumbens
Comparison of excitatory synapse number between ages with the same genotype and early life
treatment within the NAC. n = 5 (P21 Veh), 5 (P21 cHet Veh), 5 (P21 GBP), 5 (P21 cHet GBP),
6 (P21 Bup+GBP), 6 (P21 cHet Bup+GBP), 4 (P21 Bup), 5 (P21 cHet Bup), 6 (P70 Veh), 7 (P70
cHet Veh), 8 (P70 GBP), 6 (P70 cHet GBP), 7 (P70 Bup+GBP), 7 (P70 cHet Bup+GBP), 8 (P70
Bup), 7 (P70 cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Figure 25: Changes in Excitatory Synapse Number in Gabapentin Treatment in
Haploinsufficent Mice not Altered by Age Within the Prefrontal Cortex
Comparison of excitatory synapse number between ages with the same genotype and early life
treatment within the PFC. n = 5 (P21 Veh), 5 (P21 cHet Veh), 5 (P21 GBP), 5 (P21 cHet GBP),
6 (P21 Bup+GBP), 6 (P21 cHet Bup+GBP), 4 (P21 Bup), 5 (P21 cHet Bup), 6 (P70 Veh), 7 (P70
cHet Veh), 8 (P70 GBP), 6 (P70 cHet GBP), 7 (P70 Bup+GBP), 7 (P70 cHet Bup+GBP), 8 (P70
Bup), 7 (P70 cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Inhibitory Synapses Generally Decrease with Age, But Not in Gabapentin Treated Mice
Despite observing in excitatory IHC staining that synapse numbers tend to generally
decrease with age, IHC staining for GABAergic inhibitory synapses did not necessarily follow
this same trend. Significantly lower numbers of synapses were observed within the ACC (Figure
26; H = 327.8, p < 0.0001) in P70 WT mice treated with either buprenorphine or buprenorphine
in combination with gabapentin as well as in P70 cHet mice treated with vehicle control
compared with their respective P21 counterparts. However, a significantly greater number of
synapses were observed within the ACC in gabapentin treated P70 cHet mice compared with P21
mice given the same treatment. A greater synapse number was also observed between these
mouse groups within the NAC as well (Figure 27; H = 402.9, p < 0.0001). Significant increases
of this type were also observed between P70 and P21 WT mice treated with either gabapentin or
with vehicle control, yet decreases were observed in vehicle control treated cHet mice and in
buprenorphine + gabapentin treated WT and cHet mice. Within the PFC (Figure 28; H = 334.5,
p < 0.0001), P70 WT and cHet mice showed significantly greater numbers of synapses compared
to their P21 counterparts. It was only in cHet mice that significantly lower synapse numbers were
observed between P70 counterparts P21 and only in the vehicle control and buprenorphine +
gabapentin treatment groups.

96

Figure 26: Expression Level of α2δ-1 Influences Age-Related Changes in Inhibitory
Synapses Within Anterior Cingulate Cortex
Comparison of inhibitory synapse number between ages with the same genotype and early life
treatment within the ACC. n = 5 (P21 Veh), 5 (P21 cHet Veh), 5 (P21 GBP), 5 (P21 cHet GBP),
6 (P21 Bup+GBP), 6 (P21 cHet Bup+GBP), 4 (P21 Bup), 5 (P21 cHet Bup), 6 (P70 Veh), 7 (P70
cHet Veh), 8 (P70 GBP), 6 (P70 cHet GBP), 7 (P70 Bup+GBP), 7 (P70 cHet Bup+GBP), 8 (P70
Bup), 7 (P70 cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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Figure 27: Inhibitory Synapses Increase with Age in Gabapentin Treated Mice Within the
Nucleus Accumbens
Comparison of inhibitory synapse number between ages with the same genotype and early life
treatment within the NAC. n = 5 (P21 Veh), 5 (P21 cHet Veh), 5 (P21 GBP), 5 (P21 cHet GBP),
6 (P21 Bup+GBP), 6 (P21 cHet Bup+GBP), 4 (P21 Bup), 5 (P21 cHet Bup), 6 (P70 Veh), 7 (P70
cHet Veh), 8 (P70 GBP), 6 (P70 cHet GBP), 7 (P70 Bup+GBP), 7 (P70 cHet Bup+GBP), 8 (P70
Bup), 7 (P70 cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Figure 28: Inhibitory Synapses Increase with Age in Gabapentin Treated Mice Within the
Prefrontal Cortex
Comparison of inhibitory synapse number between ages with the same genotype and early life
treatment within the PFC. n = 5 (P21 Veh), 5 (P21 cHet Veh), 5 (P21 GBP), 5 (P21 cHet GBP),
6 (P21 Bup+GBP), 6 (P21 cHet Bup+GBP), 4 (P21 Bup), 5 (P21 cHet Bup), 6 (P70 Veh), 7 (P70
cHet Veh), 8 (P70 GBP), 6 (P70 cHet GBP), 7 (P70 Bup+GBP), 7 (P70 cHet Bup+GBP), 8 (P70
Bup), 7 (P70 cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Behavioral Studies
Early Life Drug Exposure Did Not Have Any Significant Effect on Performance During
Light/Dark Testing
The Light/Dark chamber is a commonly used tool for the study of anxiety-like behaviors
in rodents (Buccafusco, 2009). As part of a larger regimen of behavioral studies over the course
of seven weeks (see Figure 10), Light/Dark testing was conducted with male and female mice all
at the same age with one of two different genotypes from one of four different early life
treatments. Each mouse was video recorded for 10 minutes and allowed to pass freely between
two chambers: a Light zone chamber brightly lit from above and an unlit Dark zone chamber
covered by a roof. To first examine the possible effects the different early life drug treatments
might have on behavior, the number of entries into the Light zone from the Dark zone (Figure
29A) and the amount of time spent in the Light zone (Figure 29B) were recorded for each mouse
and the means for each treatment-genotype group were calculated. No significant differences
were observed between treatment groups in the mean number of Light Zone entries (H = 4.146, p
= 0.2461) among WT α2δ-1Thy1 mice, nor were any observed in the mean amount of time spent
in the Light zone (H = 2.247, p = 0.5228). When WT mice were compared with cHet α2δ-1Thy1
mice to determine what effect, if any, α2δ-1 genotype would have on testing behavior, no
significant differences were observed in number of entries (Figure 29C; H = 6.678, p = 0.4631)
or in time spent in the zone (Figure 29D; H = 10.86, p = 0.1447).
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Treatment and Genotype

Treatment and Genotype

Figure 29: Light/Dark Testing Performance Not Impacted by Early Life Drug Exposure or
Expression Level of α2δ-1
(A) Mean number of entries into the Light zone and (B) mean time spent in the Light zone for
each treatment group of α2δ-1Thy1 WT mice. (C) Mean number of entries into the Light zone and
(D) mean time spent in the Light zone for α2δ-1Thy1 cHet mice compared with WT mice of the
same age. n = 6 (Veh), 7 (cHet Veh), 8 (GBP), 6 (cHet GBP), 7 (Bup+GBP), 7 (cHet Bup+GBP),
8 (Bup), 7 (cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Possible Changes in Locomotor Function and Freezing Behavior in Open Field
Open Field testing can be used to study several different behavioral phenotypes in
animals, including those related to anxiety and locomotor function (Buccafusco, 2009; Sestakova
et al., 2013). In this study, mice were placed in an Open Field chamber where their movement
was recorded for 10 minutes. The number of entries into the center zone area of the field were
recorded for each mouse and the means for each treatment-genotype group were calculated
(Figure 30A). No significant differences were observed between the different treatment groups
(H = 5.101, p = 0.1646) in α2δ-1Thy1 WT mice, nor were any significant differences observed in
the mean amount of time spent in the center zone (Figure 30B; H = 1.764, p = 0.6228). The
amount of time each mouse spent in thigmotaxis near the walls of the chamber, another indicator
of anxiety-type behavior, was also recorded (Figure 30C). No significant differences were
observed between the mean times of each treatment group (F = 1.764, p = 0.3329). To assess
whether early life drug exposure impacted locomotor function, the total distance that each mouse
traveled during their time in the chamber was recorded (Figure 30D). The mean distance
traveled by mice treated with buprenorphine was significantly less than that of the mean distance
traveled by mice treated with buprenorphine + gabapentin (p = 0.0430), though neither treatment
was significantly different from the vehicle control. A difference was also seen in gabapentin
treated mice who spent significantly less time frozen (not moving in one place) than the vehicle
control (Figure 30E, p = 0.0130) and the mice treated with buprenorphine + gabapentin spent a
nearly significantly less amount of time frozen as well (p = 0.0527). These same measures were
recorded for α2δ-1Thy1 cHet mice as well and mean values were compared to those of the WT
mice for each treatment group (Figure 31). In the number of entries to the center zone (Figure
31A), time spent in the center zone (Figure 31B), time spent in thigmotaxis (Figure 31C), mean
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Figure 30: Anxiety and Locomotor Activity in Open Field Testing Potentially Impacted by
Early Life Drug Exposure
Open Field performance metrics, including (A) mean number of entries into the center zone, (B)
mean time spent in the center zone, (C) mean time spent in thigmotaxis, (D) mean total distance
traveled, and (E) time spent freezing, for α2δ-1Thy1 WT mice. n = 6 (Veh), 7 (cHet Veh), 8
(GBP), 6 (cHet GBP), 7 (Bup+GBP), 7 (cHet Bup+GBP), 8 (Bup), 7 (cHet Bup); *p < 0.05
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total distance traveled (Figure 31D), and total time spent frozen (Figure 31E), no significant
differences were observed between the genotypes ([H = 7.868, p = 0.344], [H = 4.988, p =
0.6614], [F = 0.9016, p = 0.5129], [F = 1.616, p = 0.1525], and [H = 21.51, p = 0.0059]
respectively).
Enhancement of Conditioned Place Preference Not Observed in Drug Treated Mice
Nicotine has been previously shown to produce conditioned place preference (CPP) in
rodents (Buccafusco, 2009). In this study, intraperitoneal injections of 0.5mg/kg doses of
nicotine were administered and paired with a chamber with a distinct wall pattern and floor
texture while a different chamber with a different wall pattern and floor texture was paired with
saline injections. CPP scores were calculated for each mouse based on the amount of time spent
in each chamber before and after 8 days of daily injections alternating between saline and
nicotine. The mean CPP scores for α2δ-1Thy1 WT mice from each treatment group were
compared to determine if any drug treatment produced enhanced CPP (Figure 32A). Although
each treatment group showed a positive average CPP score, indicating preference for the nicotine
paired chamber, there were no significant differences observed between treatment groups (F =
0.5944, p = 0.6243). Mean CPP scores for α2δ-1Thy1 cHet mice were then compared to WT in
each treatment group (Figure 32B). No significant differences were observed between genotypes
in any treatment group (F = 0.8514, p = 0.5509).
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Figure 31: Performance in Open Field Not Impacted by Expression Level of α2δ-1
Open Field performance metrics, including (A) mean number of entries into the center zone, (B)
mean time spent in the center zone, (C) mean time spent in thigmotaxis, (D) mean total distance
traveled, and (E) time spent freezing, for each treatment group of α2δ-1Thy1 cHet mice compared
with those of WT mice of the same age. n = 6 (Veh), 7 (cHet Veh), 8 (GBP), 6 (cHet GBP), 7
(Bup+GBP), 7 (cHet Bup+GBP), 8 (Bup), 7 (cHet Bup); *p < 0.05
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Figure 32: Neither Drug Treatment Nor α2δ-1 Expression Significantly Affected
Conditioned Place Preference
(A) Mean CPP scores for α2δ-1Thy1 WT mice across 4 early life treatment groups. (B) Mean CPP
scores for α2δ-1Thy1 cHet mice compared to WT across 4 treatment groups; n = 6 (Veh), 7 (cHet
Veh), 8 (GBP), 6 (cHet GBP), 7 (Bup+GBP), 7 (cHet Bup+GBP), 8 (Bup), 7 (cHet Bup); *p <
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
106

Decline After Day 1 Performance in FR1 Schedule Self-Administration
Self-administration of vaporized substances of abuse, including nicotine and alcohol, has
previously been used as a tool to study reinforcement-related behaviors in rodents (Cooper et al.,
2020; de Guglielmo et al., 2017; Henderson & Cooper, 2021). In this study, mice were placed in
an operant vapor chamber for one hour each day for 10 days and allowed to self-administer a
3mg/ml nicotine vapor via nose poke on a FR1 schedule (Figure 33). On Day One of the daily
sessions, α2δ-1Thy1 cHet mice that had received a vehicle control treatment demonstrated the
highest mean number of nose pokes compared to any other treatment-genotype group and had
the highest one-day mean value of any mouse group. This difference, however, did not rise to the
level of significance (H = 4.175, p = 0.7594) and was lost on the following day. No other
significant differences in mean number of nose pokes between genotype × treatment groups were
observed during the 10 days of testing.
FR3 Schedule Self-Administration Not Enhanced In Mice that Demonstrated Possible
Reinforcement
At the end of the 10 days of FR1 self-administration, the daily results for total number of nose
pokes for each mouse was reexamined to determine whether it was likely that reinforcement for
nicotine vapor self-administration was achieved. The mice chosen to participate in the 3-day FR3
schedule were as follows: three of the six WT vehicle control (two male, one female), three of
the seven cHet vehicle control (one male, two female), five of the eight WT gabapentin (one
male, four female), three of the seven WT buprenorphine + gabapentin (one male, two female),
four of the seven cHet buprenorphine + gabapentin (one male, three female), and four of the
seven cHet buprenorphine (one male, three female). Mice from cHet gabapentin (two male) and
WT buprenorphine (two female) were not included as n was too low for statistical analysis. The
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Figure 33: Number of Nose Pokes Declined After First Day of 10-Day FR1 SelfAdministration
Mean number of nose pokes for each treatment-genotype mouse group each day of 10-day FR1
self-administration testing. Vehicle control treated α2δ-1 cHet mice showed a nonsignificant
trend towards a greater number of nose pokes only on Day 1 of FR1 self-administration testing. n
= 6 (Veh), 7 (cHet Veh), 8 (GBP), 6 (cHet GBP), 7 (Bup+GBP), 7 (cHet Bup+GBP), 8 (Bup), 7
(cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Figure 34: No Significant Differences Observed Among the Mean Number of Nose Pokes of
from Last 2 Days of FR3 Self-Administration in Mice That Demonstrated Reinforcement
Mean average number of nose pokes across Days 2 and 3 of FR3 self-administration testing
(listed above standard error bars) in mice that demonstrated reinforcement during FR1 selfadministration testing. n = 3 (Veh), 3 (cHet Veh), 5 (GBP), 3 (Bup+GBP), 4 (cHet Bup+GBP), 4
(cHet Bup); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

mean number of nose pokes for each mouse for the last two days of FR3 self-administration were
calculated. Then from those values, the mean for each treatment-genotype group was calculated
(Figure 34). No significant differences were observed between any of the treatment genotype
groups (H = 3.402, p = 0.7569).
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DISCUSSION
Early Life Drug Exposure Significantly Impacts Astrocyte-Mediated Synaptogenesis via
α2δ-1
A major goal of this study was to investigate disruptions in normal synaptic development
within the mesolimbic dopamine pathway resulting from early life exposure to drugs of abuse.
To this aim, a mouse model of early life drug exposure with brain-specific knockout of α2δ-1,
the neuronal receptor for astrocyte-secreted synaptogenic thrombospondins, was developed. Four
different treatments and three possible genotypes for Cacna2d1, the gene encoding α2δ-1, within
two different age groups were tested. Average body masses for the pups were recorded and
compared across sex, treatment, and expression of α2δ-1. It was noteworthy that there were few
differences among the body masses of pups at P21. In the C57Bl/6J mouse study (see Chapter
3), several significant main effects were observed in treatment, genotype, and genotype × sex.
The C57Bl/6J dams as well showed significant differences in body mass between treatment
groups. Yet in the α2δ-1Thy1 dams, no significant differences were observed. Given that the
primary difference between these two mouse lines was brain specificity of the decreased
expression α2δ-1 versus throughout the whole body (Catterall et al., 1988; Cole et al., 2005;
Klugbauer et al., 1999; Nieto-Rostro et al., 2018; Tanabe et al., 1987), this could indicate that
whole body knockout of α2δ-1 led to greater susceptibility to drugs of abuse in terms of
interruptions of normal development.
The results of this study’s IHC experiments, much like those of the C57Bl/6J mouse
study, indicate that excitatory glutamatergic and inhibitory GABAergic synaptic populations are
significantly disrupted by early life exposure to buprenorphine and gabapentin, separately or in
combination, and that these disruptions are strongly influenced by α2δ-1 function. While
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haploinsufficiency of α2δ-1 was associated with significantly lower numbers of synapses in
some cases, brain specific knockout of α2δ-1 correlated with lower numbers of both excitatory
and inhibitory synapses within all three brain regions. This may indicate that, even when
expression of α2δ-1 was decreased, synaptogenesis induced by thrombospondins can still occur,
potentially by compensatory astrocyte-mediated signaling pathways (Baldwin & Eroglu, 2017;
Risher & Eroglu, 2020).
Early life exposure to buprenorphine in combination with gabapentin was associated with
an increase in net excitation within the mesolimbic dopamine pathway, with increased numbers
of excitatory synapses and largely unaffected numbers of inhibitory synapses. Gabapentin in
isolation, however, tended to be associated with a decrease in excitatory synapse number. These
findings are in agreement with previous research showing that normal astrocyte mediated
synaptogenesis via interaction between thrombospondin and α2δ-1 is interrupted by gabapentin
(Eroglu et al., 2009). These findings also provide further evidence that a synergistic effect occurs
between gabapentin and opioids, such as buprenorphine, that is not seen in either individual
treatment. While the precise mechanism for this interaction is not yet known, it does agree with
previous studies and patient reports of gabapentin increasing the effects of opioids (Baird et al.,
2014; Bastiaens et al., 2016; Meymandi et al., 2006) as well as the clinical finding of a unique
presentation of NAS in infants known to have been exposed to both gabapentin and opioids
(Loudin et al., 2017).
A novel finding of this study concerned the role of α2δ-1 in regulation of GABAergic
synapses. The ability of astrocytes to regulate synapse formation has largely been demonstrated
with excitatory glutamatergic synapses, and signaling involving TSP binding to α2δ-1 has been
one of the primary mechanisms through which it has been demonstrated (Christopherson et al.,
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2005; Eroglu et al., 2009; Eroglu & Barres, 2010; Risher & Eroglu, 2012, 2020). The results of
this study, however, showed that the number of inhibitory synapses was significantly decreased
in α2δ-1 Thy1 cKO mice across all three brain regions, indicating that α2δ-1 likely plays an
important role in inhibitory synaptogenesis. Previous studies have shown that astrocytes are able
to promote GABAergic synaptogenesis via secreted proteins other than TSPs (Hughes et al.,
2010) and have attempted to identify possible mechanisms by which astrocytes might promote
the development of GABAergic synapses. Such mechanisms include enhancing signaling
between BDNF and its receptor TrkB to promote GABAA receptor clustering on the surface of
post-synaptic neurons (Elmariah et al., 2005) and releasing transforming growth factor beta 1
(TGF-β1) to increase activity of NMDA glutamate receptors while initiating a kinase signaling
pathway to induce the localization and cluster formation of synaptic adhesion proteins associated
with GABAA receptor subunits (Diniz et al., 2014). Other studies have demonstrated that the
same signaling pathways responsible for increasing expression of glutamate receptors are also
responsible for increasing expression of GABA receptors (Marsden et al., 2007), highlighting the
balance between excitatory and inhibitory synaptic signaling necessary for normal CNS
development. Whether it is an absence of signaling involving α2δ-1 specifically that leads to this
decrease in inhibitory synapse formation, or whether it is a result of a balancing response to a
decrease in excitatory synapses is a subject for future investigations.
Effects of Early Life Drug Exposure on Synaptogenesis Are Not Fully Ameliorated with
Age
To determine whether the changes in synapse number induced by early life drug exposure
persist through life, IHC studies were performed with exposed α2δ-1Thy1 mice at P70 and
compared to mice at P21. Significant differences were observed between the treatment groups of
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P70 mice in both excitatory and inhibitory synapse numbers. In addition, it appeared that
changes in synaptogenesis that resulted from altered expression of α2δ-1 were not nearly as
pronounced in P70 mice as they were in P21 mice, with few significant differences being
observed between α2δ-1Thy1 WT and α2δ-1Thy1 cHet P70 mice. While the reasons for this are not
entirely known, it is possible that α2δ-1 mediated synaptogenesis primarily occurs early in life,
with its role in synaptic maintenance diminishing after a certain age. In addition, it is typically
expected for the number of synapses throughout the brain to decrease somewhat with age as
those formed early in life are removed through such mechanisms as synaptic pruning (Petralia et
al., 2014). Taken together, these results observed in P70 mice indicate that changes in synaptic
development resulting from early life drug exposure have the potential to persist throughout life
well into adulthood.
Early Life Drug Exposure Resulted in Few Significant Changes in Anxiety-Type or
Locomotor Behaviors
Another major goal of this study was to not only investigate the role of α2δ-1 in
alterations of synaptogenesis induced by early life drug exposure, but to observe what effects
these alterations may have on behaviors associated with addiction. Measures of anxiety-type
behavior included Light/Dark testing and Open Field. In behavioral tests that use a Light/Dark
chamber, it is assumed that an anxious mouse will generally prefer darker and more enclosed
spaces and avoid brightly lit, open spaces where it may feel vulnerable. For anxiety testing in an
Open Field, it is assumed that an anxious mouse will generally avoid the center of the field
where it may feel the most exposed or vulnerable and will instead spend most of its time moving
around the edge of the field close to the walls (i.e. thigmotaxis) (Simon et al., 1994). Despite
previous animal models of early life drug exposure demonstrating increased anxiety in these
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types of experiments (Ahmadalipour et al., 2015; Andersen et al., 2020; Chen H, 2015; Daly et
al., 2012; Seibenhener & Wooten, 2015), no significant differences were observed among the
mice in this study.
The Open Field was also used to measure locomotor activity to determine if any of the
chosen drug treatments were associated with motor impairments. Total distance traveled can also
be an indicator of anxiety-type behavior with more anxious mice presumed to travel a shorter
distance. It was observed that the buprenorphine treated mice did travel a significantly shorter
distance while moving around the field. Previous studies have associated changes in locomotor
activity to opioids in the past (Niikura et al., 2013; Seibenhener & Wooten, 2015; Zamani et al.,
2022) and multiple clinical studies (Burke & Beckwith, 2017; Monnelly et al., 2019) have shown
deficits in motor skills in children with a history of prenatal opioid exposure. My own study of
NAS patients (see Chapter 2) showed that the most common medical issues among the children
were musculoskeletal in nature and that the majority of those children were delayed in reaching
developmental milestones for motor skills and coordination. Clearly then, there is a potential for
prenatal drug exposure to affect the development of motor skills.
In addition, the total time spent frozen by each mouse was recorded during their Open
Field session. As another measure of anxiety, mice that spend a greater amount of time frozen in
place are assumed to be more anxious (Sestakova et al., 2013). Intriguingly, gabapentin treated
WT mice were shown to have spent significantly less time frozen (and the time spent by
buprenorphine + gabapentin WT mice was nearly significant less as well). There has been some
data to suggest gabapentin has anxiolytic properties, with male mice having been shown to spend
less time frozen in an Open Field after receiving a 30mg/kg dose injection (Sethi et al., 2005).
Intriguingly, the primary neurotransmitter whose dysregulation is most associated with disorders
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of anxiety is GABA (Nuss, 2015). Given that the glutamatergic-GABAergic synapse balance
was shown to be disrupted in mice with early life exposure to gabapentin and/or buprenorphine
(Figures 11 and 15), there is the possibility that drug-induced changes in synaptic development
and function can manifest later in life as changes in anxiety-related motor behaviors.
Reward Seeking Behaviors were not Significantly Affected by Early Life Drug Exposure or
Expression of α2δ-1
To study reward seeking behavior, mice in this study were subjected to a 10-day CPP
protocol with injections of nicotine as the reward stimulus. It was predicted that the alterations in
synaptic development within the mesolimbic dopamine pathway that have been shown to result
from early life exposure to opioids and/or gabapentin would predispose mice to experience
greater reinforcement of a rewarding stimulus (Pierce & Kumaresan, 2006). Given the high rates
of nicotine use among opioid disorder patients (Chun et al., 2009; Kohut, 2017; Streck et al.,
2020; Young-Wolff et al., 2017), it was also predicted that nicotine would be an effective
rewarding stimulus for a CPP study involving these mice. Although all but one treatmentgenotype mouse group demonstrated preference for the drug paired chamber, as evidenced by a
positive mean CPP score, no significant differences were observed between the different mouse
groups. In fact, many mice demonstrated negative CPP scores, particularly the cHet gabapentin
treated group, indicating that an aversion was developed rather than a preference. Conditioned
place aversion (CPA) is possible with nicotine, but typically only when administered in high
doses (Buccafusco, 2009). Recently, however, coadministration of morphine with nicotine was
actually shown to decrease nicotine reinforcement (Avelar et al., 2022). Clearly, the interaction
between nicotine and opioids with or without gabapentin is more complicated than this study was
able to characterize.
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The complex interaction between nicotine and early life exposure to drugs of abuse, such
as opioids, was also relevant to the vapor chamber self-administration behavioral experiments
include in this study. Mice from each treatment-genotype group were placed in nicotine vapor
self-administration chambers for daily one-hour FR1 sessions for 10 days. It was expected, based
on previous research using the same technique (Cooper et al., 2020; Henderson & Cooper, 2021)
that mice would initiate a greater number of nose pokes over time as nicotine reinforcement
occurred. However, despite most treatment-genotype groups having a high mean number of nose
pokes on Day One, especially the cHet vehicle group, daily nose poke means for all groups
declined shortly afterwards and remained relatively low over time.
Despite the lack of significant differences in daily number of nose poke between the
different treatment-genotype groups, there were still mice from six different treatment-genotype
groups that demonstrated the possibility of reinforcement. These mice were included in the
follow-up three-day one-hour FR3 self-administration sessions. No significant differences were
observed between the two-day mean number of nose pokes of each group. One potentially
noteworthy finding from this FR3 study, however, was that the majority of the mice that
demonstrated possible reinforcement were female. This may indicate that sex-related differences
in the response to rewarding substances could play a significant role in drug self-administration
studies.
There are several possible reasons for this lack of significant differences in these selfadministration studies, aside from the possibility that drug exposure may actually decrease
nicotine reinforcement (Avelar et al., 2022). In previous nicotine vapor self-administration
studies, the concentration of nicotine in the administered puffs of vaporized PGVG were 6mg/ml
nicotine salt, double the concentration used in this study. In addition, previous studies placed
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mice in vapor chambers for two-hour or three-hour FR1 sessions each day rather than the onehour sessions used in this study (Cooper et al., 2020; Henderson & Cooper, 2021). Given that
reinforcement had already been seen in mice that followed the procedures of previous studies,
nicotine concentrations and session times were lower in this study as a means to assess whether
reinforcement was enhanced in mice that had been exposed to drugs of abuse during early life
development. It was reasoned that if any group of mice in this study demonstrated and significant
reinforcement, it could be taken as a sign that that group had shown enhancement in the
reinforcement of nicotine vapor self-administration.
Another possible explanation for why mice failed to show significant reinforcement for
self-administration may have been related to the procedure through which it was tested. Mice
were required to learn to associate the action of poking their nose into one of two holes and the
turning on of a light with the administration of a three-second puff of nicotine vapor within their
chamber. Previous studies have demonstrated, however, that learning and memory may be
impaired in both humans and rodents with a history of prenatal exposure to drugs of
(Ahmadalipour et al., 2015; Chen H, 2015; Egil Nygaard et al., 2015; Oei et al., 2017; A. Ornoy,
2003) abuse. Therefore, it is possible that any behavioral studies that require mice to learn
relatively complex behaviors may not be accurate measures unless the impaired learning and
memory in those mice can be controlled for or removed as a potentially confounding factor.
Overall, this study demonstrated the impact of early life drug exposure, α2δ-1 expression,
and age on synaptic development within three brain regions associated with the mesolimbic
dopamine pathway. It achieved this through the use of α2δ-1Thy1 mice and multiple IHC studies
designed to examine and compare numbers of excitatory and inhibitory synapses between
different early life drug treatments, α2δ-1 genotypes, and ages. This study also attempted to
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connect the findings from these IHC to the results of multiple behavioral experiments examining
behaviors related to addiction and activity within the mesolimbic dopamine pathway. Although
few significant differences were observed between mice belonging to different groups based on
treatment or genotype, future studies may be informed by the behavioral results of these mice. A
greater understanding of the long-term effects of early life drug exposure on synaptic
development and behavior will hopefully lead to improved health outcomes for human patients
impacted by drug abuse.
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CHAPTER 5
CONCLUSIONS
Reflection on Major Findings from These Investigations
The results of the studies included in this dissertation collectively paint a larger picture
about the effects of prenatal exposure to drugs of abuse. First, a chart review of NAS patients
who appeared at a treatment center for follow-up clinic appointments was carried out. This study
observed several trends among these patients describing, among other factors, the drugs most
commonly abused by patient mothers, the health problems most commonly seen among the
patients, and the extent of the developmental delays seen in the patients.
Second, IHC and confocal fluorescent microscopy studies examined the numbers of
excitatory glutamatergic and inhibitory GABAergic synapses within the ACC, NAC, and PFC of
mice in two different age groups (P21 and P70) with one of three possible genotypes for
expression of the Ca2+ channel subunit α2δ-1 (WT, Het, or cKO) exposed to one of four different
treatments during early life development (5 mg/kg buprenorphine, 30 mg/kg gabapentin, a
combination of both drug doses, or a vehicle control). It was demonstrated that excitatory and
inhibitory synaptic populations are significantly disrupted by early life exposure to
buprenorphine and gabapentin, separately or in combination, and that these disruptions are
strongly influenced by the level of expression of α2δ-1 and by age.
Third, a regimen of behavioral experiments was carried out in early life drug exposed
mice to determine what effects the different drug treatments and the different expression levels
of α2δ-1 might have on behaviors related to addiction. There were indications that locomotor
activity may be impacted by early life exposure to buprenorphine as well as indications that
anxiety-related activity may be lessened in mice exposed to gabapentin during early life
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development. Although few significant differences were observed between mice belonging to
different groups based on treatment or genotype, future studies looking at other behaviors or
utilizing different experimental methods may be informed by the behavioral results of these
mice.
Potential Weaknesses and Directions for Future Studies
Although the experiments included in this dissertation were planned and carried out as
carefully and methodically as possible, there were limitations and potential weaknesses to these
studies that may have influenced the results. It is important to acknowledge for the mouse studies
included in this dissertation that the timeline for rodent neurodevelopment does not correlate
directly with that of humans. A newborn mouse is approximately neurodevelopmentally
equivalent to a human fetus in the late second trimester (Ross et al., 2015). This was accounted
for when planning the drug dosing schedule, for while efforts were made to replicate prenatal
drug exposure in human patients as closely as possible, the period of time during which a great
deal of synaptogenesis occurs in the developing mouse brain also needed to be captured within
the timeframe.
The significant differences between rodent and human fetal development warrant the
need for noninvasive, ethical methods of studying human tissues at early developmental stages.
Tissue from post-mortem humans, for example, has been effectively and reproducibly used to
study opioid receptor gene expression (Peng et al., 2012). Recent advances have also been made
in three-dimensional in vitro culture techniques have allowed for the production of brain
organoids derived from induced human pluripotent stem cells that have been used to study
changes in neuronal protein expression and cell maturation. This model system is non-invasive
and allows for the study of living, functional human tissue, making it a potentially invaluable
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tool in the study of the effects of drug exposure on the developing human brain (Di Lullo &
Kriegstein, 2017). Recent models such as these could lead to a more accurate understanding of
the natural processes disrupted by exogenous opioids, or other drugs of abuse such as
gabapentin, and could elucidate the role of glial cells in these processes. Going forward, it would
be constructive to pursue the opportunities that are now available to explore the effects of opioid
exposure on human CNS development at the cellular and molecular level.
In the future, the data gained from the studies described in this dissertation will need to
be expanded to account for other important variables with the potential to influence either
astrocyte-mediated synaptogenesis or the effects of drugs of abuse on the developing CNS. The
inclusion of α2δ-1 knockouts in the P70 timepoint IHC studies as well as in the behavioral
studies would more completely demonstrate the importance of α2δ-1 in determining the effects
of early life drug exposure on synaptic development and behavior. In these studies, neither
C57Bl/6J α2δ-1 KO nor α2δ-1Thy1 cKO pups were born and/or survived to P21 in sufficient
numbers to be included in this study. This is likely due to a lack of α2δ-1 being deleterious to the
health of mice, especially in those treated with buprenorphine and/or gabapentin. Given enough
time, sufficient numbers of α2δ-1Thy1 cKO pups could likely have been produced and utilized in
behavioral and IHC studies. In an effort to reduce the number of mice needed to complete the
studies described in this dissertation, all mice used for behavioral studies were used for every
experiment listed in the seven-week regimen in the order in which they are listed. These same
mice were sacrificed and perfused at the end of those studies (at P70) to then be used in IHC
studies. The various forms of stress experienced by those mice and the repeated nicotine
treatments they received over the course of those behavioral studies may have impacted their
performance in behavioral studies occurring later in the schedule and may have affected synapse
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numbers within the mesolimbic dopamine pathway. One way in which this potential
confounding factor could be addressed is by allowing for a separate cohort of mice for
behavioral studies. Without the need to carry out all behavioral studies within the seven-week
period between P21 weaning and P70 sacrifice dates, studies could be spread over a longer
period of time, with significant “down-time” breaks in between each study. This could allow
mice in this cohort to recover from the effects of stress and nicotine treatments before beginning
another potentially stressful behavioral trial.
Another significant change that could have been made to this study would have been to
examine sex-related differences between male and female mice. There has been significant
evidence to suggest that not only are the brains between males and female different in key
structural areas, including potential sex-specific synaptogenic responses to astrocyte-secreted
TSP-2 (Mazur et al., 2021; Uhl et al., 2022), there are important differences in their prenatal
development. During fetal development, the presence of male or female specific hormones is
necessary for sex-dimorphic behaviors and sex-specific differences in the size and structure of
certain brain regions (Ehrhardt & Meyer-Bahlburg, 1979; Xin et al., 2019).
Sex hormones may also modify the effects of prenatal drug exposure on neurological
development. The expression of opioid receptors within the brains of rats has been shown to be
influenced by the presence of estrogen and progesterone (Cruz et al., 2015), but the exact role of
ovarian hormones in the development of the endogenous opioid system remains unclear. Animal
studies have shown that the presence of estrogen and progesterone can influence the expression
of mu and kappa opioid receptors (Cruz et al., 2015). One study examining learning and memory
showed significant sex-related differences in the ability of rats prenatally exposed to morphine to
solve the mazes. The presence or absence of ovarian hormones was implicated as the reason for
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these sex-related differences (Šlamberová et al., 2001). Another investigation into learning and
memory deficits used a symmetrical maze and a radial arm maze (RAM) to show significant sexrelated differences in the ability of prenatal morphine-exposed rats to solve the mazes
(Šlamberová et al., 2001). Male rats required less time to complete the symmetrical maze, while
both sexes showed deficits in completing the RAM in a similar amount of time to sex-matched
controls. The presence or absence of ovarian hormones was implicated as the reason for these
sex-related differences, since ovariectomized females prenatally exposed to opioids exhibited
poor performance that was rescued by hormone replacement injections.
Additional evidence for an interaction between sex hormones and opioids during
development can be observed in the presentation of human infants with NAS. Multiple clinical
studies have shown that rates of NAS are higher in male than in female newborns, and that male
NAS patients are more likely than females to require treatment for their symptoms (Charles et
al., 2017; Stevens et al., 2018). Differences in head circumference and types of symptoms
between males and females have also been observed (Stevens et al., 2018). In terms of behavior,
male infants with a history of prenatal opioid exposure have been shown to score higher than
females on cognitive tests of habituation (Jones et al., 2010). Studies such as these highlight the
need to consider sex-related differences both in animal model basic research and in clinical
studies.
In clinical studies, such as the one performed in this dissertation, it is important to
consider environmental factors that can indirectly influence the health and wellbeing of children
and can also be potential confounders when investigating incidence of NAS or drug abuse in
general. Such factors can include race (Becker & Newsom, 2003), geographic location (Berry et
al., 2016; J. Brown et al., 2018), socio-economic status (M. Kim et al., 2018), and stability of
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home life (Berry et al., 2016; Asher Ornoy et al., 2001). Lower socio-economic status has long
been known to be associated with poorer health in general (Braveman & Gottlieb, 2014). It has
been found that improving the economic resources available to infants born into families with
low socio-economic status can significantly improve brain function within key regions (TrollerRenfree et al., 2022). However, there is evidence to suggest that prenatal drug exposure can
impact neurological development even when social factors are controlled for in children raised in
different, more stable households than the ones into which they were born (Egil Nygaard et al.,
2015; Egil Nygaard et al., 2018; A. Ornoy, 2003; Asher Ornoy et al., 2001). In studies of a
medical condition as inextricably linked to environmental factors as NAS, it will always be
important to attempt to isolate the effects of drug exposure from the effects of the surrounding
environment as much as possible.
Aside from the behaviors studied and the behavioral experiments utilized in this
dissertation, there are several other aspects of behavior with the potential to be affected by early
life drug exposure and/or alterations in synaptic development within the mesolimbic dopamine
pathway. Studies designed to examine memory and learning, such as social interaction, novel
object recognition, and passive avoidance test, have been used in rat models of prenatal opioid
exposure and have shown significant differences between drug treated and control subjects
(Ahmadalipour et al., 2015; Chen H, 2015). The learning difficulties and generally poorer
performance in school seen in children with a history of prenatal drug exposure may also be
attributed to deficits in learning and memory (Egil Nygaard et al., 2015; Oei et al., 2017; A.
Ornoy, 2003). An investigation into these types of behaviors may also prompt examinations of
the hippocampus, the brain region predominantly involved in learning and memory (Rubin et al.,
2014), which has been shown to interact with the mesolimbic dopamine pathway and to have
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altered development and function as a result of exposure to drugs of abuse (Belujon & Grace,
2011; Lisman & Grace, 2005). There are many opportunities for additional studies utilizing this
mouse model and experimental paradigm.
Final Remarks
Neonatal abstinence syndrome has negatively impacted the lives an untold number of
children and their families. Increasing the collective understanding of this condition and the
factors that cause it will be critical to improving methods for preventing and treating it as well as
meeting the unique developmental needs of the children who develop it. This dissertation is
intended to add to that body of knowledge by identifying a potential molecular target in α2δ-1.
This protein, as well as the broader mechanism of astrocyte-mediated synaptogenesis, may
become the focus of studies exploring treatments and preventative methods designed to drive
down the incidence rates of NAS that have risen to epidemic levels in the United States in recent
years. It is the intention of the author that this dissertation further the cause of using scientific
and clinical research towards improving the health and wellbeing of patients and the vulnerable
populations most impacted by NAS and substance use disorders.
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